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Weight of evidence assessment 
A B S T R A C T   
Lidocaine has not been associated with cancer in humans despite 8 decades of therapeutic use. Its metabolite, 
2,6-xylidine, is a rat carcinogen, believed to induce genotoxicity via N-hydroxylation and DNA adduct formation, 
a non-threshold mechanism of action. To better understand this dichotomy, we review literature pertaining to 
metabolic activation and genotoxicity of 2,6-xylidine, identifying that it appears resistant to N-hydroxylation and 
instead metabolises almost exclusively to DMAP (an aminophenol). At high exposures (sufficient to saturate 
phase 2 metabolism), this may undergo metabolic threshold-dependent activation to a quinone-imine with po-
tential to redox cycle producing ROS, inducing cytotoxicity and genotoxicity. A new rat study found no evidence 
of genotoxicity in vivo based on micronuclei in bone marrow, comets in nasal tissue or female liver, despite high 
level exposure to 2,6-xylidine (including metabolites). In male liver, weak dose-related comet increases, within 
the historical control range, were associated with metabolic overload and acute systemic toxicity. Benchmark 
dose analysis confirmed a non-linear dose response. The weight of evidence indicates 2,6-xylidine is a non-direct 
acting (metabolic threshold-dependent) genotoxin, and is not genotoxic in vivo in rats in the absence of acute 
systemic toxic effects, which occur at levels 35 × beyond lidocaine-related exposure in humans.   
1. Introduction and background 
Lidocaine, widely used in human and veterinary medicine for over 8 
decades, is on the World Health Organisation list of essential medicines 
(WHO, 2019) as one of mankind’s safest, most effective local anaesthetic 
agents. However, 2,6-xylidine (2,6-dimethylaniline, CAS No. 87-62-7), a 
metabolite of lidocaine in humans (Parker et al., 1996) and food pro-
ducing species (Thuesen and Friis, 2012; Hoogenboom et al., 2015) has 
been identified as a rat carcinogen by the U.S. National Toxicology 
Program (NTP, 1990), raising questions regarding safety of exposure. 2, 
6-Xylidine (2,6-dimethylaniline, CAS No. 87-62-7) is an aromatic amine. 
Its structure and pathways of metabolism are shown in Fig. 1. 
In the NTP study, 2,6-xylidine was administered to rats in diet for 2 
years at doses from 300 to 3000 ppm (estimated to equate to 15–150 
mg/kg/day), and increased incidences of nasal tumours in both sexes, 
and neoplastic nodules in livers of females, were reported in high dose 
groups (NTP, 1990). In 1993, the International Agency for Research on 
Cancer (IARC) concluded that 2,6-xylidine is possibly carcinogenic to 
humans i.e. group 2B (IARC, 1993). When lidocaine is administered to 
humans at maximum daily recommended levels of 300–400 mg/day, 
(which amounts to 50% 2,6-xylidine by molar weight) the maximum 2, 
6-xylidine exposure would be 2.5–3.5 mg/kg/day, i.e. well below the 
lowest dose used in the NTP study. Lidocaine has given consistent 
negative results in a variety of standard in vitro and in vivo genotoxicity 
tests (see Supplementary Table 1), and clinical monitoring over 80 years 
of therapeutic use in humans has not identified evidence to suggest a 
causal association between lidocaine use and cancer formation (Hold-
croft and Nouette-Gaulain, 2014; Friedman and Ury, 1983; Selby et al., 
1989; Fuzier et al., 2009). To better understand this dichotomy there is a 
clear need to examine the genotoxicity and carcinogenicity of 2,6-xyli-
dine including pathways of potential metabolic activation and evi-
dence of a potential threshold for these effects. 
2,6-xylidine is included in the SIDS database (SIDS, 2012), and a 
number of reports have been published reviewing its carcinogenicity 
and genotoxicity. The most recent review was conducted by the Health 
Council of the Netherlands (2015) who concluded that “2,6-xylidine is 
suspected to be carcinogenic to man, and recommends classifying the 
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compound in category 2”. The majority of these reports however, 
summarise results of genotoxicity studies without assessment of the 
biological relevance of each individual study. Furthermore, in these 
assessments, N-hydroxylation of 2,6-xylidine to form dimethylphenyl 
N-hydroxylamine (DMHA, Fig. 1), with subsequent esterification and 
DNA adduct formation, has been presumed as the putative mechanism of 
carcinogenicity in the rat, in line with that of carcinogenic polycyclic 
aromatic amines (Beland and Kadlubar, 1985). This is generally 
Abbreviations: 
2-AMBA 2-amino-3-methylbenzoic acid 
8-OH-dG 8-hydroxy-deoxyguanosine 
Aprt adenine phosphoribosyltransferase gene 
BMD benchmark dose 
BWL bodyweight loss 
CA chromosomal aberrations 
CHL Chinese hamster lung 
CHO Chinese hamster ovary 
dG deoxyguanosine 
DMHA dimethylphenyl N-hydroxylamine 
DMAP 4-hydroxy-2,6-xylidine or 3,5-dimethyl-4-aminophenol 
DMQI 2,6 dimethylxylidine quinoneimine 
EMS ethyl methanesulfonate 
GLP good laboratory practice 
Gpt bacterial guanine-hypoxanthine 
phosphoribosyltransferase gene 
Hb haemoglobin 
Hprt hypoxanthine-guanine phosphoribosyltransferase gene 
IARC International Agency for Research on Cancer 
met-Hb met-haemoglobin 
LOQ level of quantification 
MF mutant frequency 
MN micronucleus or micronuclei 
MTD maximum tolerated dose 
NCE normochromatic erythrocytes 
NNK 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone 
NO(A)EL no-observed adverse effect level 
NTP National Toxicology Program 
OECD Organisation for Economic Co-operation and Development 
PCE polychromatic erythrocytes 
PoD point of departure 
ROS reactive oxygen species 
TK toxicokinetic 
Tk thymidine kinase locus 
UDS unscheduled DNA synthesis 
WoE weight of evidence  
Fig. 1. 2,6-Xylidine metabolism – major and minor pathways.  
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considered a non-threshold, direct genotoxic mechanism of action. Ul-
timately, however (as detailed below), there is little in vivo evidence to 
support N-hydroxylation of 2,6-xylidine as a putative model of carci-
nogenicity in the rat. Importantly, metabolic studies identify that, by 
virtue of its structure, 2,6-xylidine is resistant to N-hydroxylation and 
instead is metabolised almost exclusively via 4-hydroxylation to an 
aminophenol (2,6-dimethylaminophenol or DMAP). Aminophenols 
generate pathology via different metabolic activation pathways (char-
acteristically threshold affected) as compared with N-hydroxylamines. 
This has important implications that have generally not been considered 
in previous reviews. 
In this paper we review potential pathways of metabolic activation 
and genotoxicity of 2,6-xylidine and perform a critical review of the 
published literature pertaining to its genotoxic potential, including the 
biological relevance of individual studies. Additionally, a new in vivo 
study has been performed to investigate genotoxic dose response in rats 
and evidence for a metabolic threshold for genotoxic effects, and also to 
address some identified deficiencies in the database. The data are then 
assessed in terms of weight of evidence (WoE) for the genotoxic po-
tential of 2,6-xylidine. 
2. Review of potential pathways of metabolic activation and 
genotoxicity of 2,6-xylidine 
2.1. N-hydroxylation (formation of DMHA) 
N-hydroxylation of polycyclic aromatic amines is the primary step in 
a well described pathway of metabolic activation, which may result in 
mutagenesis and carcinogenesis. Following N-hydroxylation in vivo, co- 
oxidation reactions with haemoglobin (Hb) result in met-haemoglobin 
(Met-Hb) and nitrenium ion formation (Fig. 1). Nitrenium ions are 
“hard” electrophiles which (via esterification) have a propensity to form 
irreversible covalent bonds with Hb and DNA resulting in adducts. DNA 
adducts of carcinogenic polycyclic aromatic amines are typically formed 
via covalent linkage of the amide nitrogen to the C8 of 2′-deoxy-
guanosine (dG), leading to C8-dG adducts. These are bulky and possess 
conformational heterogeneity, resulting in a variety of mutagenic out-
comes. The most common involve frameshift mutations and base sub-
stitutions, predominantly G → T, and also G → C transversions (Kozack 
et al., 2000). This is a direct, non-threshold mechanism of DNA damage. 
Monocyclic aromatic amines may also be susceptible to N-hydroxylation 
predisposing to nitrenium ion, and Hb or DNA adduct formation. There 
is less evidence however, to indicate these smaller adducts are similarly 
mutagenic (Neumann, 2005). However, It should be noted that adducts 
are generally considered a biomarker of exposure rather than effect 
(Jarabek et al., 2009); they may be rapidly cleared or repaired and do 
not necessarily lead to persistent genetic damage or mutations. 
Nevertheless, in support of the hypothesis that 2,6-xylidine induces 
genotoxicity via this mechanism: DMHA has been identified as a 
metabolite of 2,6-xylidine in vitro following incubation with rat hepatic 
microsomes (Kirkland et al., 2012): Synthesized N-acetoxy metabolites 
do form C8-dG adducts when reacted with DNA in vitro (Marques et al., 
1997); Hb and DNA adduct formation (particularly prominent in 
ethmoid tissue) has been documented in rats following 2,6-xylidine 
administration (Bryant et al., 1994; Duan et al., 2008; Short et al., 
1989b; Jeffrey et al., 2002), and synthesized DMHA is also reported to 
be mutagenic in Ames tests (Nohmi et al., 1984; Marques et al., 1997; 
Jeffrey et al., 2002). Relevance to humans has been concluded by 
finding DMHA as a metabolite of lidocaine in urine (albeit at extremely 
minor levels constituting <1% of the dose (Nelson et al., 1978)). Addi-
tionally, an “association” between bladder cancer and 2,6-xylidine 
exposure has been reported (Gan et al., 2004; Tao et al., 2013). This, 
however, was based on finding elevated 2,6-xylidine haemoglobin (Hb) 
adducts in bladder cancer patients after diagnosis (and hence many 
months or years after cancer initiation). As Hb-adducts are short-lived, a 
causative association cannot be concluded. Critically these studies failed 
to examine post-diagnosis lidocaine exposure as a confounding variable. 
Lidocaine is frequently used for pain mitigation in bladder cancer pa-
tients, and may cause raised 2,6-xylidine Hb-adducts (Bryant et al., 
1994). As such, it is arguably the most likely aetiology of increased 
Hb-adducts in bladder cancer patients. 
Ultimately however, despite the in vitro findings above, DMHA has 
not been detectable as a metabolite of 2,6-xylidine in vivo in rats. 
Metabolic studies (both in vitro and in vivo) identify that 2,6-xylidine is 
overwhelmingly metabolized via 4-hydroxylation to DMAP, rather than 
N-hydroxylation to DMHA. Whilst minor DMHA production has been 
detectable in vitro (Kirkland et al., 2012; Gan et al., 2001), there has been 
no success detecting any evidence of DMHA production and/or esteri-
fication to N-acetoxy derivatives in vivo in the rat (Lindstrom et al., 
1963; Hardy, 1986; Short et al., 1989a). In addition, 2,6-xylidine does 
not share the same propensity for Hb and DNA adduct formation as other 
aromatic amines. Sabbioni (1992) identified that when fed to rats orally, 
2,6-xylidine did not share the Hb binding capacity of other aromatic 
amines, noting that the methyl groups in the 2 and 6 positions (either 
side of the amine) near abolished Hb binding, and appeared to cause 
steric interference, impeding N-hydroxylation and subsequent forma-
tion of reactive nitrenium ions responsible for protein reactivity through 
acetoxy or sulphate esterification. Fishbein and McClelland (1987) 
similarly reported a poor yield of nitrenium ion from DMHA in aqueous 
conditions. Consistent with this, rat studies of DNA adduct formation 
identified that 2,6-xylidine only induces very weak adduct formation 
that has generally only been detectable following high dose adminis-
tration (>60 mg/kg; Duan et al., 2008) and/or following 7–9 days of 
repeated high repeated dose administration (262.5–310 mg/kg/day; 
Short et al., 1989b; Jeffrey et al., 2002). Furthermore, there is little 
evidence to support N-hydroxylation as the putative mechanism of 2, 
6-xylidine DNA adduct formation. Jones and Sabbioni (2003), for 
example, did not find evidence of DNA adduct formation in the livers of 
rats treated orally with high dose DMHA, and DNA adduct character-
ization studies found a different pattern of adduct formation in vitro from 
reacting DNA with synthesized N-acetoxy-2,6-xylidine, than is charac-
teristic of the carcinogenic polycyclic aromatic amines. Although C8dG 
and C8dA adducts were present, these were in minor proportions, and 
ring-as opposed to N-derived adducts were found to predominate 
(Gonçalves et al., 2001; Jones and Sabbioni, 2003; Marques et al., 1997). 
Additionally, in a C57BL/6 mouse study with 2,6-xylidine administered 
at 83 μg/kg by intraperitoneal dosing, Skipper et al. (2006) reported that 
DNA adducts, although detectable at low levels in urinary bladder and 
liver 4 h following administration, were considerably depleted by 
additional DNA purification (suggesting the possibility of adduct for-
mation with intranuclear proteins rather than DNA), and also showed 
rapid further depletion over time. DNA adducts were cleared from the 
bladder with a half-life of 8 h, and from the liver with a half-life of 10 h, 
inconsistent with long-lasting irreversible covalent DNA binding. 
Although rapid clearance of DNA adducts does not necessarily imply a 
lower risk for mutation or cancer, for most identified carcinogens, ad-
ducts persist over a period of weeks. As commented by Bieler et al. 
(2007) “several studies have found a positive correlation between car-
cinogen–DNA adduct levels and persistence in relation to target organ 
specificity for tumour formation, suggesting the critical importance of 
persistent carcinogen–DNA adducts”. Finally, although synthesized 
DMHA (at a concentration of 10 nM (i.e. 1.37 μg)/plate) was found to 
induce mutagenicity in the Ames test (Nohmi et al., 1984), 2,6-xylidine 
was not similarly mutagenic when incubated with rat hepatic micro-
somes, despite the presence of DMHA in biologically produced con-
centrations (Kirkland et al., 2012). Nelson et al. (1978) furthermore 
reported that “Preliminary carcinogenicity testing of 2,6-di-methylphe-
nylhydroxylamine through the National Cancer Institute testing pro-
gram has produced no tumors in Swiss albino mice”. Together these 
findings thus throw considerable doubt on N-hydroxylation as the pu-
tative mechanism of genotoxicity and carcinogenicity of 2,6-xylidine in 
the rat. 
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2.2. 4-Hydroxylation (formation of DMAP) 
An alternate potential mechanism of pathology is via metabolic 
activation of DMAP to form 2,6-dimethylquinoneimine (DMQI, Figs. 1 
and 2). DMAP, the major metabolite of 2,6-xylidine, is an aminophenol, 
with structural similarity to acetaminophen (also known as 4-acetoxy-p- 
aminophenol or paracetamol). Aminophenols are electrophilic and 
highly protein reactive. In biological systems this promotes their rapid 
conjugation with glucuronide and/or sulphate and elimination in the 
urine, which is one of the major pathways of detoxification and elimi-
nation of xenobiotic substances (Bray et al., 1952). At high levels of 
production however, phase 2 metabolism may saturate. In this situation, 
aminophenols (in their free state) are subject to co-oxidization reactions 
(such as with Hb) forming quinone-imines, which are reactive electro-
philes and oxidizing agents (Dahlin et al., 1984; Guengerich et al., 
1985). Met-Hb and reactive oxygen species (ROS) are concomitantly 
produced in this reaction, which may be further exacerbated by redox 
cycling resulting in oxidative stress (Kiese, 1966; Nakajima and Kusu-
moto, 1963). Quinone-imine formation may also occur in tissues via 
cytochrome p450 two electron oxidation reactions, similarly resulting in 
ROS production and redox cycling, albeit without met-Hb formation 
(Porubek et al., 1986). Oxygen radicals are cytotoxic and are also known 
to cause DNA damage (G:C → A:T transitions and G:C → T:A trans-
versions), induce C8 DNA adducts and can be a cause of spontaneous 
mutations (Hsie et al., 1986; Kreutzer and Essigmann, 1998; Suzuki and 
Kamiya, 2017). Chronic cytotoxicity and/or oxidative injury are well 
known pathological mechanisms that predispose to carcinogenicity 
(Okada 2002, 2014; Strzelczyk and Wiczkowski, 2012). The body 
however has strong anti-oxidant defence mechanisms that prevent 
and/or rapidly repair oxidative damage (Davies, 2001; Lan et al., 2004). 
Unlike nitrenium ions, quinone-imines are “soft” electrophiles. They 
are Michael acceptors and readily react with soft nucleophiles like 
sulfhydryl residues on cysteine in glutathione and proteins. Reactions 
with nitrogen nucleophiles such as lysine and histidine are much slower 
compared to that of sulfur nucleophilic additions, although they have 
been reported (Bolton et al., 2017; Ravindra et al., 2016). High affinity 
for glutathione acts to detoxify quinone-imines by reduction or conju-
gation and elimination via the mercaptopurine pathway, and prevents 
redox cycling and associated ROS production. In overproduction sce-
narios, however, glutathione depletion may occur, resulting in unfet-
tered redox cycling and ROS production sufficient to overwhelm cellular 
antioxidant defence, leading to secondary cytotoxic and genotoxic ef-
fects (Athersuch et al., 2018; Hinson et al., 2010). Amino-phenols thus 
characteristically act as threshold cytotoxins and secondary genotoxins. 
For example, activation of acetaminophen to N-acetyl-p-quinone-imine 
(NAPQI) via this pathway is believed to be the putative mechanism of 
cytotoxicity and DNA injury following paracetamol overdose. Cytotoxic 
and clastogenic effects may, however, occur at much lower concentra-
tions in vitro, since in vitro systems do not contain co-factors necessary 
for phase 2 metabolism and may be deficient in glutathione, meth-
aemoglobin reductase and/or other anti-oxidant substances. 
There is considerable evidence to suggest that DMAP may undergo 
metabolic activation and induce pathology via this pathway in vitro, and 
in vivo in rats following high dose 2,6-xylidine administration sufficient 
to saturate phase 2 metabolism. In vitro, in its free state, DMAP is re-
ported to be an unstable molecule that rapidly oxidises non- 
enzymatically to quinone-imine derivatives (Abdel-Rehim et al., 2006; 
Tam et al., 1990). In biological systems in vitro, in the absence of phase 2 
metabolites, DMAP is haem-reactive and a potent inducer of met-Hb 
(Hartman et al., 2017) as well as intracellular ROS production with 
associated clastogenic effects (Chao et al., 2012). In vivo however, DMAP 
undergoes extensive and rapid glucuronide and/or sulfur conjugation, 
such that there is negligible availability of free compound to participate 
in haem co-oxidation reactions. Conjugation greatly reduces protein 
reactivity, and promotes its excretion in the urine (Skipper et al., 2010). 
In rats, following 2,6-xylidine administration, DMAP is found in urine 
almost exclusively (>99%) in conjugated form (Lindstrom et al., 1963). 
This is also the case in humans following lidocaine administration, 
(Keenaghan and Boyes, 1972; Tam et al., 1987; Nelson et al., 1977). 
Following high dose 2,6-xylidine administration to rats however, there 
is evidence to suggest that phase 2 metabolism of DMAP may saturate, 
such that haem co-oxidation may occur, resulting in met-Hb and DMQI 
formation. DMQI-glutathione conjugates have been detected in urine 
and hepatic tissue of rats following intraperitoneal doses of 90 mg/kg in 
rats (Jeffries et al., 1998; Rosen et al., 1984) and a statistical increase in 
met-Hb formation is seen following 80 mg/kg intravenous (i.v.) doses of 
Fig. 2. Pathways of quinone-imine formation from DMAP  
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2,6-xylidine in rats (Lindstrom et al., 1969). Repeat dose toxicity studies 
identify an oral dose of 50 mg/kg 2,6-xylidine as a no-effect level 
(NOEL) for met-Hb production in rats (Yamaguchi et al., 2005). Chronic 
dosing at, or acute dosing significantly above these threshold levels 
therefore has the potential to saturate glutathione binding and deplete 
glutathione, leading to cytotoxic and genotoxic (most likely clastogenic) 
effects. In this regard, it is notable that 2,6-xylidine Hb and DNA adducts 
have only been detected in rats following high and/or prolonged dosing, 
seemingly at or above levels associated with saturation of phase 2 
metabolism of DMAP and evidence of DMQI/Met-Hb production. Bryant 
et al. (1994) reported 2,6-xylidine adduct formation in rats follows 
intraperitoneal doses of 900 mg/kg. As quinone-imines may bind to Hb 
via thioether bonds, 2,6-xylidine Hb adducts detected following such 
high dose administration may indicate DMQI- rather than 
DMHA-derived adducts, as previously presumed. Similarly, given the 
lack of significant formation of DMHA in vivo, and that ring-, instead of 
N-derived DNA adducts predominate, and DMQI – histone binding is 
reported (Ravindra et al., 2016), it is possible that these could derive 
from DMQI reaction with intranuclear proteins (as contaminants), 
and/or with DNA, although evidence of direct DNA binding currently 
remains elusive (Skipper et al., 2010). 
3. Review of published data pertaining to the genotoxicity of 
2,6-xylidine 
Given the reported carcinogenicity of 2,6-xylidine in rats, and 
possible modes of action, a critical review of its genotoxic potential is 
important. 2,6-Xylidine has been tested in a number of in vitro and in vivo 
test systems for gene mutations, chromosomal damage and DNA dam-
age. Some tests have also been performed on DMHA and DMAP. The 
various published in vitro and in vivo genotoxicity studies (as of May 
2020) are summarised in Supplementary Table 2. Comments on the 
strengths and weaknesses of these studies, and their biological rele-
vance, are given below. 
3.1. Bacterial reverse mutation (Ames) tests 
3.1.1. With 2,6-xylidine 
Standard Ames tests conducted prior to the NTP carcinogenicity 
study in 1990 were predominantly negative. Hartman et al. (1979), 
Nelson et al. (1978), Zimmer et al. (1980), and Florin et al. (1980) all 
reported negative results in Ames tests. Nohmi et al. (1984) also re-
ported no mutagenic activity for 2,6-xylidine in the absence of S9, 
however noted a low mutagenic activity (39 revertants/μM) in 
S. typhimurium strain TA100 in the presence of 30% rat liver S9. (The 
metabolic activation conditions were described in Nohmi et al., 1981). 
No conclusions of biological relevance can be drawn in view of the 
weakness of the response and the high S9 concentration. However, it 
should be noted that the range of strains used in all of the above refer-
enced studies did not meet current OECD guideline recommendations 
(OECD, 1997), in that strains to detect chemicals acting via oxidative 
mechanisms, inducing cross-links or inducing mutations at A-T-rich re-
gions of the DNA (such as S. typhimurium TA102, or E. coli WP2 strains) 
were not included. 
Ames tests were performed and reported as part of the NTP carci-
nogenicity study report (NTP, 1990), but with no detail on methodology. 
S. typhimurium strains TA100, TA1535, TA1537, TA98 were studied with 
and without rat and hamster S9. All were clearly negative, but again 
neither TA102 nor an E. coli strain was included. Additional NTP studies 
were subsequently undertaken and reported by Zeiger et al. (1988). 
Studies were undertaken in 3 different laboratories with S. typhimurium 
strains TA97 (one laboratory), TA98, TA100, TA1535 (all three labo-
ratories) and TA1537 (one laboratory), with and without 3 different 
concentrations (5, 10 and 30%) of hamster and rat liver S9. Again, 
TA102 or an E. coli strain were not included. Modified standard 
reporting was used and included categories of “equivocal” (increase less 
than 2× control and sporadic, not reproducible or not dose dependent) 
and “weakly positive” (increase less than 2 × control, dose dependent, 
reproducible), which the authors noted to be highly subjective and to 
vary between laboratory sites. Using this new terminology, they 
concluded 2,6-xylidine was non-mutagenic when tested with 10% S-9 at 
one laboratory (TA98, TA100, TA1535), and weakly mutagenic (when 
tested with 30% S-9) at the other 2 sites. (A more detailed review of the 
data on the NTP website and in Zeiger et al. (1988) is given in Supple-
mentary Document 1). 
In addition, a “weakly positive” response (<1.5-fold increases over 
concurrent controls) was subsequently reported for 2,6-xylidine by 
Kugler-Steigmeier et al. (1989), in S. typhimurium strain TA100 with 
20% rat S9. Results were negative in strain TA98. Weakly positive re-
sults (<2 × control) in TA100 and (<3 × control) in TA1535 with 
metabolic activation (rat S9), were also reported by Masumori et al. 
(2005a), in studies undertaken for the Japanese Chemical Evaluation 
Database under OECD Guideline 471 (OECD, 1997). 
It is usually accepted that 2-fold increases in TA100 revertants, or 3- 
fold increases in TA1535 revertants, constitute biologically meaningful 
positive responses, but reproducible increases of less than these levels, 
particularly if accompanied by evidence of a dose response, cannot be 
considered clearly negative. Thus, in laboratories that used 30% hamster 
S9 in the studies mentioned above and further detailed in Supplemen-
tary Document 1, biologically meaningful responses in TA100 revertants 
were seen. In other experiments and other laboratories, with other 
strains and with different activation conditions, there were weaker or 
equivocal responses, but overall, the data do indicate weak (<2 ×
control), but reproducible mutagenic responses for 2,6-xylidine in 
TA100 under non-standard metabolic activation conditions (20–30% 
S9). 
In the most recent and comprehensive study, undertaken to comply 
with OECD (1997) guidelines, Kirkland et al. (2012) obtained clearly 
negative results in Ames tests using all of the currently required strains 
(TA98, TA100, TA1535, TA1537 and E. coli WP2uvrA) in the absence of 
S9, and in the presence of 10 and 30% rat S9 or 30% human S9. This 
study included bacterial strains over-expressing N-acetyl transferase 
(YG1024 and YG1029), and DMHA was documented to be metabolically 
produced and present in the media. 
Hamster S9, which had given some weakly positive responses in the 
NTP studies (Zeiger et al., 1988) was not used in the studies by Kirkland 
et al. (2012), since this is not recommended for routine regulatory 
testing. Furthermore, the metabolism of 2,6-xylidine may vary consid-
erably between species. Rats and humans are known to metabolise 2, 
6-xylidine almost exclusively via 4-hydroxylation and/or phase 2 
conjugation. Dogs however, produce a wider range of metabolites in 
vivo, including 2-amino-3-methylbenzoic acid (2-AMBA), along with 
trace amounts of 2,6-dimethylnitrosobenzene (Hardy, 1986; Short et al., 
1989a). Guinea pigs have reduced capacity for 4-hydroxylation but 
increased N-conjugation (Keenaghan and Boyes, 1972). The metabolism 
of 2,6-xylidine in hamsters has not been examined, and may not reflect 
rat or human metabolism or be relevant for assessment of human 
mutagenic risk. Therefore, the recent robust negative results of Kirkland 
et al. (2012) with human and rat S9 (even at elevated levels such as 
30%) should be seen as more relevant than the weak positive results 
with hamster S9. 
3.1.2. With the N-hydroxy metabolite (DMHA) 
Nelson et al. (1978) reported no genotoxicity for DMHA in 
S. typhimurium strain TA1538 ± S9, however this may not be the most 
sensitive strain. DMHA was found to be mutagenic in S. typhimurium 
TA100 (Nohmi et al., 1984; Marques et al., 1997; Jeffrey et al., 2002), 
however all 3 studies used synthesized DMHA at concentrations that 
may not be achievable when formed in biological systems by meta-
bolism of 2,6-xylidine, as discussed in Kirkland et al. (2012). Marques 
et al. (1997) reported that synthesized DMHA was the most mutagenic of 
several mono and di-substituted anilines in S. typhimurium TA100, but 
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that this did not result from a higher efficiency of adduct formation; 
DNA adduct efficiency of N-acetoxy-2,6-xylidine was 2% versus up to 
9% in less or non-mutagenic arylamines. Similarly, Nohmi et al. (1984) 
reported strong (100-10,000-fold increases) genotoxicity for DMHA in 
strain TA100 with or without S9. In the same set of studies, however, 
DMHA did not cause reductions in the activity of Bacillus subtilis trans-
forming DNA. The authors concluded that while other phenyl-
hydroxylamine derivatives caused DNA damage through the generation 
of active molecular species, such as nitrenium ions, without any enzy-
matic activation, DMHA was an exception, and appeared to require 
further metabolic activation by bacterial enzymes to stimulate muta-
genesis. A possibility in this regard, is conversion to DMAP via “Bam-
berger re-arrangement” (the process of chemical re-arrangement of 
phenylhydroxylamines to aminophenols). DMHA is known to be rapidly 
converted to DMAP in the presence of liver microsomes and CYP 2E1 
(Vmax 6.9 nmol/min/mg, Km 500 μM) (Gan et al., 2001). Bamberger 
rearrangement also occurs in bacterial cells catalyzed by lyase and 
mutase bacterial enzymes, as detailed by Nadeau et al. (2003). 
The recent studies of Kirkland et al. (2012) investigated biological 
production of DMHA from 2,6-xylidine in vitro and also included tests 
with bacterial strains that over-express N-acetyl transferase. These au-
thors showed that DMHA was formed from high concentrations of 2, 
6-xylidine by rat and human S9, (predominantly 30% S9), and ana-
lysed the P450 enzymes involved and the Michaelis Menten kinetics of 
the reactions. The results indicated very low production levels of DMHA 
from 2,6-xylidine, with a Km of 46 and a Vmax of 0.04 nmol/min/mg. 
However, despite the presence of DMHA, mutagenic responses were not 
observed in strain TA100, or in the YG1024 and YG1029 strains over-
expressing N-acetyltransferase. This is clearly in contrast to the findings 
from Nohmi et al. (1984), Marques et al. (1997), and Jeffrey et al. 
(2002), despite all the experiments in Kirkland et al. (2012) including 
pre-incubation methodology, which should have ensured the bioavail-
ability of any metabolites. 
An explanation may revolve around the disparity in concentration of 
DMHA (per plate) employed in the trials, based on whether it was 
formed “biologically” or added “extraneously” (see Supplementary 
Table 2 for comparison of concentrations). The kinetics of DMHA for-
mation in biological systems, in contrast to instant addition of DMHA, 
may also be a factor. Whilst adduct-related genotoxicity is generally 
regarded as a non-threshold process, genotoxicity secondary to ROS 
production will only occur at concentrations which overwhelm the 
cellular anti-oxidant defence capabilities. ROS production may not 
occur from low levels of DMHA produced from biological systems (such 
as used by Kirkland et al., 2012) and/or may be insufficient to over-
whelm anti-oxidant processes in the cultured cells and hence may not 
result in genotoxic effects. By contrast, ROS production from rapid 
exposure to higher concentrations of DMHA, either added directly or 
through conversion to DMAP, may rapidly overwhelm the anti-oxidant 
capacity of the in vitro system and result in oxidative effects. 
3.2. Studies in mammalian cells in vitro 
3.2.1. Gene mutation tests in mammalian cells 
3.2.1.1. With 2,6-xylidine. A mouse lymphoma Tk mutation study, 
initially reported in an abstract by Rudd et al. (1983) was subsequently 
reported in more detail in a retrospective review by Mitchell et al. 
(1997), where somewhat more detail was given. At the highest con-
centration tested in the absence of S9 (0.8 μL/mL), the response was 
considered “inconclusive or inadequately tested”, most likely indicating 
insufficient concentrations were tested over the critical range of 10–20% 
relative total growth (RTG) to be able to evaluate the results as clearly 
positive or negative. A “limited positive” result was concluded in the 
presence of induced S9 but only at the top concentration, 0.25 μL/mL 
(approximately 250 μg/mL), and this was defined as a 
concentration-related increase in mutant frequency (MF), where the 
spontaneous mutant frequency was >20 × 10− 6, and an induced MF of 
>70 × 10− 6 was observed at RTG >10% for at least one concentration. 
This study was performed prior to current recommendations (OECD, 
2016a), and before it was common practice to “size” the mutant col-
onies. However, it appears (from the Rudd et al., 1983 abstract) that 
small colony mutants were predominantly induced indicating a clasto-
genic mode of action. It is not known how much cytotoxicity was 
induced at the top concentration of 2,6-xylidine, and therefore it is not 
known whether the results would be considered biologically relevant 
when judged using current criteria. 
3.2.1.2. With 2,6-xylidine and/or metabolites DMHA, DMAP. Chao et al. 
(2012) tested 2,6-xylidine and 3,5-xylidine (0–1000 μM), as well as their 
aminophenol and N-hydroxy metabolites (5–100 μM and 5–250 μM 
respectively) in the presence of a human S9 mix, for cell survival and 
mutation in Chinese hamster ovary (CHO) cells at the Aprt locus in AA8 
and UV5 CHO cells, and at the Gpt locus in AS52 cells. ROS production 
and DNA damage were also examined in AS52 cells in a comet assay in 
the absence and presence of ascorbate and N-acetyl cysteine (NAC), a 
readily absorbed glutathione precursor. Since preliminary studies 
showed “no material differences” between 2,6- and 3,5-xylidine, the 
more detailed studies, and much of the data presented in the paper, are 
from the latter. Unfortunately, the authors do not describe what they 
consider to be “material differences”. Furthermore, the potential for N- 
versus 4-hydroxylation will differ between these 2 isomers, with N-hy-
droxylation being more likely with the 3,5-isomer due to less steric 
hindrance from the positions of the methyl groups. Steric factors may 
also affect glutathione affinity (Rosen et al., 1984), such that mutagenic 
activity of 3,5-xylidine may exceed that of 2,6-xylidine. No mutant 
frequency data were presented for 2,6-xylidine, however characteriza-
tion of the nature of mutations induced by 2,6-xylidine (with S9) was 
undertaken by sequencing some gpt mutant colonies from the CHO AS52 
cells (presumably from a preliminary experiment). There was a signifi-
cant increase in G:C to A:T transitions, which is the most common base 
substitution induced by oxidative stress (Kreutzer and Essigmann, 
1998). It is not known under what conditions (concentration, cytotox-
icity) these mutants were induced, or the magnitude of any mutagenic 
responses. It was reported that 2,6-xylidine (0–100 μM) in the presence 
of human S9 did not induce ROS production, but no details were given. 
DMAP and DMHA, however, induced prominent ROS production over 
the same dose range (further detailed below). Since AS52 cells can 
detect both clastogens and gene mutagens, it is not known what mode of 
action may have led to any mutagenic responses seen with 2,6-xylidine. 
The aminophenols were far more toxic and induced mutations at 
lower concentrations than the N-hydroxylamines, and both hydroxy 
derivatives were more toxic than the anilines activated by exogenous S9. 
DMAP and DMHA induced intracellular ROS production in a dose 
dependent manner over the dose range studied (up to 250 μM). The 
aminophenols of both isomers exhibited potent ROS production at 
concentrations up to 25 μM (3.4 μg/mL), exceeding by several fold the 
ROS induced by higher concentrations (100 μM; 13.7 μg/mL) of the N- 
hydroxylamines. Similarly, using the comet assay, DMAP induced a 
statistically significant increase in DNA strand breaks at 50 μM (6.8 μg/ 
mL, the highest level tested). Comet induction doubled, (but did not 
reach statistical significance) for DMHA at 250 μM (34 μg/mL). Ascor-
bate and NAC were protective against strand breaks in both cases. There 
was thus a strong association between ROS production and mutagenicity 
in the CHO AS52 cells. It is relevant to note that AS52 cells are known to 
be sensitive to oxidative injury (Kim et al., 2003), a finding that was 
corroborated by the trials above and identified to be secondary to 
ascorbate deficiency. Mutagenic effects seen in CHO AS52 cells were not 
seen in AA8 or UV5 cells, unless first depleted of ascorbate in this series 
of studies. Together with the findings from cell lines treated with 3, 
5-xylidine and its metabolites, (including absence of evidence of 
D.J. Kirkland et al.                                                                                                                                                                                                                             
Regulatory Toxicology and Pharmacology 119 (2021) 104838
7
increased mutagenicity of the N-hydroxy metabolite in cells lines 
over-expressing N-acetyl transferase 2 (NAT2)), the authors concluded 
“Comparative evaluation of the results indicates that the principal mechanism 
of mutagenic action is likely to be through redox cycling of intracellularly 
bound aminophenol/quinone imine structures to generate ROS rather than 
through formation of covalent DNA adducts”. 
Jang et al. (2006) examined various metabolites 2,6- and 3,5-xyli-
dine for induction of cytotoxicity and Hprt mutations in human lym-
phoblastoid TK6 cells and HCT116 colon cancer cells. Further details 
were reported by Skipper et al. (2010). All metabolites induced dose and 
time dependent cytotoxicity, but aminophenols were more cytotoxic 
than N-hydroxy metabolites, and 3,5- were more cytotoxic than 2,6-xyli-
dine metabolites. When tested for Hprt mutagenicity, Skipper et al. 
(2010) reported that both the aminophenol and N-hydroxy metabolites 
of 3,5-xylidine were clearly mutagenic but that DMHA was not muta-
genic over the same dose range. (Cytotoxicity and mutagenicity of 2, 
6-xylidine and DMHA in AS52 cells was noted in brief, as presumably 
later reported in detail in Chao et al. (2012) as discussed above). 
3.2.2. Chromosomal aberration (CA) tests in mammalian cells 
There are only 2 publications investigating induction of chromo-
somal aberrations (CA) in mammalian cells in vitro, both with 2,6-xyli-
dine. Masumori et al. (2005b) treated Chinese hamster lung (CHL/IU) 
cells for 6 h with 2,6-xylidine at concentrations of 0, 303, 606 and 1212 
μg/mL in the absence of S9, and at 0, 633, 744 and 876 μg/mL in the 
presence of induced rat liver S9. According to the Japanese Toxicity 
Testing of Environmental Chemicals Data Base, (also referenced in the 
SIDS report, 2012), the study was undertaken under GLP standards to 
OECD Guideline 473 (OECD, 1997b), but did not comply fully because it 
only included short term (6 h) exposures. Reduction in cell growth to 
50% was seen at around 1212 μg/mL in the absence of S9 and some-
where between 744 and 876 μg/mL in the presence of S9. A 
dose-dependent increase in structural CA was observed, reaching highly 
significant levels at the top concentration in the absence of S9, and at the 
top 2 concentrations in the presence of S9. The aberrations consisted 
principally of chromatid breaks and exchanges. 
Galloway et al. (1987) tested 2,6-xylidine (+/-S9) for induction of 
CA in CHO cells as part of the NTP trials (NTP, 1990). The concentra-
tions tested ranged from 900 to 1200 μg/mL and from 1200 to 1400 
μg/mL in the absence and presence of induced rat liver S9 respectively. 
Precipitate was present at all concentrations tested, with and without S9. 
The latest revisions to OECD guidelines recommend that, for mamma-
lian cell tests with insoluble substances, the highest concentration tested 
should be the lowest concentration exhibiting precipitate at the end of 
treatment, but at the time these studies were conducted this limitation 
was not specified in the OECD guideline (OECD, 1997b). In this respect 
the results may be questionable. Whilst a slight increase in CA frequency 
(to 8% cells with CA, excluding gaps and endoreduplication) was seen at 
1000 μg/mL in the absence of S9, this was compared to a very low 
solvent control frequency (1% cells with CA), and frequencies as high as 
8% had been seen in solvent control cultures in other experiments re-
ported in the same publication. Therefore, this mid-dose level response 
may well be considered not to be biologically relevant. The most sig-
nificant increase in CA frequency (-S9) was at 1200 μg/mL (19% cells 
with CA, excluding gaps and endoreduplication), but only 16 cells (out 
of a target of 100 cells) could be scored, and since there was no con-
current measure of cytotoxicity, it is highly likely that significant cell 
killing occurred at this concentration, which could indirectly lead to 
increased chromosomal breakage. In the presence of S9, significant in-
creases in % cells with CA, excluding gaps and endoreduplication 
(19–88%) were seen at all 3 concentrations analysed. However, in the 
absence of a concurrent measure of cytotoxicity, the possibility of 
chromosomal damage at some of the concentrations tested being an 
indirect consequence of high levels of cell killing cannot be ruled out. 
3.3. In vivo studies 
All published in vivo studies were performed with 2,6-xylidine, and 
none were performed with the metabolites. 
3.3.1. Mouse micronucleus (MN) tests in bone marrow or peripheral blood 
Parton et al. reported on 2 different study designs to investigate the 
induction of MN in mouse bone marrow by 2,6-xylidine. In the first 
study (Parton et al., 1988) male ICR mice were dosed once by oral 
gavage with 87.5, 175 and 350 mg/kg, the top dose being approximately 
50% of the oral LD50. Animals were sacrificed 24, 48 and 72 h later, 
smear slides made and stained with Wright’s Giemsa stain, and 1000 
polychromatic erythrocytes (PCE) per animal scored for MN. This is 
much lower than the 4000 PCE/animal currently recommended (OECD, 
2016b). Bone marrow toxicity was determined as the ratio of PCE to 
normochromatic erythrocytes (NCE). MN frequencies in vehicle control 
animals were normal and were significantly increased by positive con-
trol treatment (100 mg/kg cyclophosphamide, sampled at 24 h). There 
was no evidence of bone marrow toxicity from 2,6-xylidine treatment 
based on PCE:NCE ratio, and no plasma samples were taken for deter-
mination of the presence of 2,6-xylidine, so exposure of the bone 
marrow was not verified. MN frequencies in 2,6-xylidine-treated ani-
mals were generally similar to vehicle controls at all doses and sampling 
times. Although a 2.2-fold increase in MN frequency was seen at the top 
dose at the 48-hr. sampling time, it was not significantly different, and 
the authors concluded the result was negative. 
In the second study Parton et al. (1990) dosed male ICR mice by oral 
gavage on 1, 2 or 3 consecutive days with 2,6-xylidine at 75 or 375 
mg/kg/day. Animals were sacrificed 24 h after the last dose, smear 
slides made and stained with Wright’s Giemsa, and 2000 PCE/animal 
scored for MN. Although numbers of PCE scored are an improvement on 
the earlier study, this is still less than currently recommended (OECD, 
2016b). No bone marrow toxicity was evident according to PCE:NCE 
ratios, and no plasma samples were taken for determination of the 
presence of 2,6-xylidine, so exposure of the bone marrow was not 
verified. MN frequencies in vehicle control animals were a little higher 
than in the previous study, but still considered normal, and were 
significantly increased by positive control treatment (100 mg/kg 
cyclophosphamide given once only and sampled at 24 h). MN fre-
quencies in 2,6-xylidine-treated mice were similar to controls at both 
dose levels and after 1, 2 or 3 doses, and there were no significant 
differences. 
Kohara et al. (2018) also reported negative results from a mouse 
bone marrow micronucleus test. Male ddY mice (the same animals as 
used in a comet assay, discussed below) were administered 200 mg/kg 2, 
6-xylidine by oral gavage once per week for 4 weeks. Bone marrow cells 
were collected 24 h after the final dose. There were 3 males per group 
and no concurrent positive control. Only 1000 PCE/animal were scored 
for MN, which is much lower than the 4000 PCE/animal currently rec-
ommended (OECD, 2016b). No bone marrow toxicity was evident, and 
no plasma samples were taken for determination of the presence of 2, 
6-xylidine, so exposure of the bone marrow was not verified. There 
was no increase in MN PCE following treatment with 2,6-xylidine. 
Kohara et al. (2018) also reported negative results in a mouse MN 
test in peripheral blood PCE (reticulocytes) of transgenic MutaTMMouse. 
Mice received 2,6-xylidine by oral gavage on a single occasion at a dose 
of 100 mg/kg. Cells were examined for MN in the peripheral blood 48 h 
following treatment. There were 5 animals per group, with positive and 
negative control groups, although the positive control data were not 
reported. It is not clear how many cells were scored, or whether they 
were scored manually or by flow cytometry. There was no increase in 
MN frequency above concurrent control. 
In the latest version of the OECD guideline (OECD, 2016b) it is 
stressed that negative results can only be considered meaningful if there 
is evidence of bone marrow exposure. None of the above studies 
included any measurement of test chemical in plasma, and, as stated 
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above, there was no bone marrow toxicity. There were no 2,6-xyidine 
absorption data reported in these mouse studies, however, 2,6-xylidine 
is rapidly and completely absorbed following oral dosing in rats (IARC, 
1993). Rapid absorption with widespread tissue distribution, (including 
to bone marrow) has been documented in rats fed 63 mg/kg 
radio-labelled 2,6-xylidine by gavage (NTP, 1990), and doses of 226 
mg/kg/day by gavage have been documented to result in plasma levels 
of 0.36 μg/mL in rats (Yasuhara et al., 2000), and therefore it is 
reasonable to assume that absorption from the GI tract into the systemic 
circulation does occur following oral dosing in rodents. Thus, the bone 
marrow would have been exposed during these in vivo mouse MN 
studies. 
3.3.2. In vivo/in vitro unscheduled DNA synthesis (UDS) test in rat liver 
The in vivo/in vitro rat liver UDS test became popular in the late 
1980s to early 1990s because it provided an additional tissue (other than 
bone marrow or blood) in which to detect genotoxic effects in rodents, 
and was particularly useful at detecting hepatocarcinogens that pro-
duced only weak or no effects on MN induction in peripheral tissue such 
as bone marrow. However, its sensitivity has been questioned (see 
Kirkland and Speit, 2008; Hardy et al., 2017), and it is less widely used 
today, having been superseded by new tests in regulatory strategies, 
such as rodent transgenic mutation assays and the comet assay, which 
provide improved sensitivity and opportunities to sample a much wider 
range of tissues. Nonetheless, a UDS test on 2,6-xylidine could be 
considered relevant since the liver will be a primary site of metabolism 
of 2,6-xylidine, particularly in rats (the only species in which carcino-
genicity has been documented). 
Mirsalis et al. (1989) dosed Fischer 344 rats on a single occasion by 
oral gavage with 2,6-xylidine at 40, 200 and 850 mg/kg. Animals were 
sampled 2 and 12 h later, livers were perfused, suspensions of hepato-
cytes seeded on to coverslips, and incubated with 3H-thymidine to be 
incorporated into any replicating DNA. UDS was scored autoradio-
graphically, counting the numbers of silver grains over the nucleus and 
over 2 comparable areas of cytoplasm for a total of 150 cells per animal. 
Net nuclear grain counts (nucleus minus cytoplasm) in vehicle control 
animals were <zero (which is normal), and significant responses (high 
net nuclear grain counts) were induced by the positive control chemicals 
(dimethylnitrosamine and 2-acetaylaminofluorene). Net nuclear grain 
counts in all groups of 2,6-xylidine-treated animals were <zero and 
therefore similar to vehicle controls. Although a negative result was 
correctly concluded, and, as discussed above, it is clear that exposure of 
the liver would have occurred following oral dosing, negative results 
with the UDS assay should be viewed with caution. 
3.3.3. Transgenic mouse gene mutation assay 
Kohara et al. (2018) dosed male MutaTMMice with 100 mg/kg 2, 
6-xylidine given weekly for 4 weeks by oral gavage. There were 4–5 
mice per group. Positive controls received benzo(a)pyrene and negative 
controls received the vehicle (olive oil). The DNA was extracted from the 
nasal tissues, bone marrow, and liver on day 7 after the last dosing. This 
treatment and sampling regime is somewhat different from that rec-
ommended in OECD guideline 488 (OECD, 2013). Lambda phage con-
taining the LacZ transgene were prepared by the ex vivo packaging 
method, and appropriate strains of E. coli C were infected with the 
reconstituted lambda phage. LacZ mutations were measured in galE- 
bacteria, and cII mutations were measured in G1225 (hfl-) bacteria. 
Numbers of total plaques and numbers of mutant plaques were counted, 
and the mutation frequency (MF = number of mutants/total number of 
plaques) was calculated. In addition, the cII sequence was analyzed by 
an ABI 310 Genetic Analyzer. There was no increase in the frequency of 
LacZ or cII gene mutations in the liver or bone marrow (n = 5 mice), 
however there was a marginal increase in mutation frequency of both 
genes in the nasal tissue (4 out of 5 treated mice provided acceptable 
data), reaching 2× the control value (3 out of 5 control mice provided 
acceptable data), although this did not reach statistical significance for 
the cII gene. The mutations were predominantly A:T to G:C transitions 
and G:C to T:A transversions. It should be noted that no historical control 
mutant frequency data were presented, so the biological relevance of 
this increase is unclear. 
3.3.4. Comet assays in multiple tissues of mice 
Kohara et al. (2018) dosed male ddY mice with 2,6-xylidine by oral 
gavage at 200 mg/kg (10 mL/kg) on a single occasion and bone marrow, 
liver, lung and kidneys were isolated 3 and 24 h after the last dosing for 
detection of DNA damage (the single cell gel/comet assay). There were 3 
males per group, but no positive control. The numbers of cells scored 
was given as 500 cells/group, and the comets were categorized into 5 
different classes, dependent on extent of DNA migration, rather than the 
more conventional %tail DNA or tail moment measures. Positive results 
were obtained in lung, kidney, and liver at 3 h But were not observed at 
24 h after the last dosing. With so little detail it is difficult to assess 
whether the study would comply with the OECD Guideline 489 (OECD, 
2016c) that was subsequently developed and adopted. 
Sasaki et al. (1999) tested 2,6-xylidine for induction of DNA strand 
breaks (comet assay) in 8 different mouse tissues. Male ddY Mice (n = 4 
per group) were dosed orally, by gavage, with a single dose (the 
maximum tolerated dose, 350 mg/kg, which is 50% of the LD50), and 
tissues were sampled 3, 8 and 24 h later. Animals dosed with 2,6-xyli-
dine showed reddish staining of urine, which may be indicative of 
haemolysis. Overt cyanosis due to met-haemoglobinaemia occurred in 
aniline-treated mice dosed at this level in the same publication, and it is 
thus likely that sub-clinical met-Hb formation was also induced in 2, 
6-xylidine-treated animals (this dose level is 7× the no-effect level for 
met-Hb formation in rats). Even low levels of met-Hb can cause the 
oxygen dissociation curve to shift towards the left, which can result in 
tissue anoxia. Furthermore, the presence of met-haemoglobinaemia in-
dicates the co-production of ROS during haem co-oxidation reactions. 
Untreated animals were used as a zero-time control. Isolated nuclei 
(50/tissue) were scored for comets. This is slightly unusual since most 
practitioners use whole cells, but, as stated in OECD guideline 489 
(OECD, 2016c), both isolated nuclei and whole cells are considered 
equally acceptable. The authors express comet results as tail length, 
whereas the recommended parameters, % tail DNA or tail moment, take 
into account the amount of DNA in the tail as well as its length. The 
results with 2,6-xylidine were unusual. Statistically significant increases 
in comet tail length were seen in stomach and bladder at the 8-h sam-
pling time only – but were negative at 3 and 24 h, which are the rec-
ommended sampling times, according to OECD guideline 489 (OECD, 
2016c). It is difficult to understand the biological relevance of a DNA 
strand breakage result only seen at a non-standard sampling time. Sig-
nificant increases in comet tail length were seen at 3 and 8 h (but not 24 
h) in brain, and at 8 and 24 h in lung tissue. Although the tail lengths 
were greater than were seen in untreated animals (zero-time controls), 
and must therefore be considered positive responses, the DNA strand 
breaks were only seen in tissues that did not correspond with known 
tumour risk in rats, (although nasal tissue was not examined). In mice 2, 
6-xylidine had no tumour modifying effect in NNK-induced pulmonary 
proliferative lesions in rasH2 transgenic and non-transgenic CB6F1 
mice, despite exposure to doses of 3000 ppm for 26 weeks, or 2000 ppm 
for 53 weeks, (Takahashi et al., 2003), although it did promote 
inflammation, metaplasia and hyperplasia in the nasal tissue of 
NNK-treated rasH2 mice, and proliferation of Bowmans glands in rasH2 
and non-transgenic mice (Minemura et al., 2003). In the paper by Sasaki 
et al. (1999), the comet assay was positive with all chemicals that form 
met-Hb, and may therefore have been a marker of acute oxidative stress. 
The unusual time pattern of responses seen with 2,6-xylidine could be 
indicative of an acute oxidative injury event which was subsequently 
resolved. Sections of each tissue were fixed, embedded and sectioned for 
histopathological examination, but no microscopic signs were observed 
following any treatment, implying that there was no significant induc-
tion of necrotic/apoptotic or degenerated cells, i.e. the comet responses 
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could not be attributed to general cytotoxicity. However, the comet 
assay is an indicator test and, like the UDS assay, detects DNA damage 
which might be effectively repaired or be lethal, and does not neces-
sarily indicate an ability to induce stable genetic alterations (such as 
mutations). 
3.4. Summary and conclusions from critical review of the literature 
2,6-xylidine showed weakly positive responses in TA100 (and once 
in TA1535) in the presence of non-standard metabolic conditions 
(hamster S9; 20 or 30% rat S9) in some trials, while in other tests, 
including the most recent study carried out to current OECD guidelines, 
the results were clearly negative. 2,6-xylidine induced chromosomal 
aberrations in hamster ovary and lung cells in vitro at high concentra-
tions or under cytotoxic conditions, and induced gene mutations in 
eukaryotic test systems in vitro, associated with evidence of ROS pro-
duction and oxidative injury. In vivo, 2,6-xylidine was considered non- 
clastogenic in micronucleus assays, in the peripheral blood and bone 
marrow of mice after oral doses up to a dose of 375 mg/kg, however, no 
measurement of test chemical in plasma was made in these studies. An 
oral in vivo UDS assay in rat liver was clearly negative up to a dose of 
850 mg/kg, however, exposure of the liver was not checked. A trans-
genic rodent gene mutation assay was weakly positive (2× control) in 
nasal tissue after 4× weekly oral doses of 100 mg/kg, but bone marrow 
and liver were negative. Although AT to GC transitions and GC to TA 
transversions were observed, the result is of questionable biological 
relevance because of the absence of historical control mutant frequency 
data. Two in vivo comet assays with 2,6-xylidine were reported to be 
positive, but the tissues that responded and the timings of the responses 
were inconsistent and difficult to interpret. The doses used may have 
induced acute systemic toxicity. 
In vitro studies with DMHA showed that genotoxic effects are present 
in prokaryotic and eukaryotic test systems using synthesized DMHA, but 
not when it was generated biologically within the test system. DMAP 
was shown to be more toxic and more mutagenic than DMHA, and both 
hydroxy derivatives were more toxic than metabolically-activated 2,6- 
xylidine. In an in vitro comet assay with DMHA and DMAP, the posi-
tive responses were attributed to redox cycling of intracellularly bound 
aminophenol/quinone imine structures to generate ROS. 
Overall, there is evidence that 2,6-xylidine has weak genotoxic 
characteristics in vitro and is able to induce DNA damage in vivo, 
following high dose administration, however, there are no clear positive 
findings that 2,6-xylidine exposure results in lasting genotoxic effects 
due to stable genetic damage. The results would support a threshold- 
dependent metabolic activation pathway, such as may occur second-
ary to metabolic activation of DMAP to DMQI with redox cycling and 
ROS production, only evident at doses or concentrations sufficient to 
overwhelm phase 2 metabolism of DMAP and glutathione detoxification 
of DMQI. Furthermore in vivo, anti-oxidant defence mechanisms exist to 
prevent, and/or rapidly repair oxidative DNA injury (Davies, 2001; Lan 
et al., 2004) and therefore any cytotoxic and/or genotoxic effects 
resulting from ROS production would also be expected to exhibit a 
threshold. 
Given the confusing pattern of in vivo results with 2,6-xylidine, the 
use of methods that do not comply with the most current guidelines, and 
the absence of systemic exposure data, it was felt important to conduct a 
new, robust in vivo study. 
4. New in vivo micronucleus and comet study in Sprague-Dawley 
rats 
In view of the above comments, the aim of this study was to examine 
the genotoxic dose response of 2,6-xylidine, associated toxicokinetic 
parameters and markers of metabolic-related oxidative stress in vivo in 
rats, to better elucidate the potential presence and nature of a metabolic 
threshold for genotoxic effects. The study was performed using Sprague 
Dawley rats, as this is currently the only animal species to have shown 
carcinogenic effects. Bone marrow was sampled for MN since the pub-
lished MN studies had only been conducted in mice, and the comet assay 
was performed in liver, since this is a primary site of metabolism, and in 
nasal tissue since this is the primary site for tumours in rats. The study 
was conducted at Integrated Laboratory systems, Inc. (ILS) in August 
2019 in accordance with United States Environmental Protection 
Agency’s (U.S. EPA) Good Laboratory Practice (GLP) Regulations (40 
CFR Part 160) and OECD guidelines TG474 (OECD, 2016b) and TG489 
(OECD, 2016c). All data underwent quality control review. All proced-
ures were in compliance with the Animal Welfare Act Regulations, 9 CFR 
1–4 and animals were handled and treated according to the Guide for the 
Care and Use of Laboratory Animals. 
4.1. Test chemicals 
2,6-Xylidine (99.4% pure; batch no. STBH6422) and the vehicle 
(corn oil) in which it was formulated, were purchased from Sigma- 
Aldrich (St. Louis, MO, USA). The positive control chemical, ethyl 
methanesulfonate (EMS) was also purchased from Sigma-Aldrich, and 
was formulated in sterile filtered 0.9% saline. 
4.2. Animals 
Hsd:Sprague Dawley® rats (strain Harlan; SD), aged 8–10 weeks, 
were purchased from Envigo Laboratories (Frederick, MD, USA). The 
numbers of animals were 38 males plus 38 females for the MN/comet/ 
bioanalytical phases, 23 males plus 23 females for histopathology/uri-
nalysis, and 20 males plus 20 females for toxicokinetic (TK) analysis. 
They were housed singly or 2–3 per cage in polycarbonate cages with 
micro-isolator tops, with absorbent heat-treated hardwood bedding 
(Northeastern Products Corp., Warrensburg, NY). Animal rooms were 
maintained at a temperature of 20.5–23.1 ◦C, and humidity of 
39.0–74.8%, with lighting on a 12/12-h light/dark cycle. Certified 
Purina Pico Chow No. 5002 (Ralston Purina Co., St. Louis, MO) and 
reverse osmosis treated tap water (City of Durham, NC) were provided 
ad libitum. Rats were acclimated for 7 days prior to the start of treatment 
for the main study, or for 2 days prior to dosing for TK analysis. Each 
animal was uniquely identified by ear punch prior to the start of the 
study. The weight ranges of the animals at the start of treatment were 
240.7–290.3 g for the males, and 191.3–221.3 g for the females. 
4.3. Basic study design 
The basic design was as described by Bowen et al. (2011). Groups of 
male and female rats were dosed by oral gavage either with 2,6-xylidine 
(5 dose levels per sex), or the vehicle (corn oil), or EMS, daily for 3 
consecutive days at approximately 0, 24, and 45 h. At 48 h. (i.e. 3 hrs. 
after the final dose) bone marrow was sampled for MN analysis; liver 
and nasal tissues were sampled for comet analysis and for the analysis of 
2,6-xylidine and metabolite concentrations, and markers of oxidative 
stress (8-OH-dG and glutathione levels). Additional groups of rats were 
dosed similarly, with harvest of liver and nasal tissues for potential 
histopathological analysis. Separately, groups of satellite rats were 
similarly dosed with 2,6-xylidine or vehicle, and blood was collected via 
a jugular vein catheter 1, 2, 4, 8, and 24 h post final dose (±1 min) for 
toxicokinetic analysis. 
4.4. Selection of dose levels 
The dose levels for 2,6-xylidine were selected following the conduct 
of a range finder study in which all animals of both sexes were admin-
istered the test substance via oral gavage at 0, 24 and 45 h. Animals 
given 2,6-xylidine at 400 mg/kg (females) and 500 mg/kg (males) 
exhibited some clinical signs of toxicity symptoms but survived to the 
terminal necropsy (3 h following the final dose). Animals at higher dose 
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levels exhibited severe toxic signs and did not survive to the terminal 
necropsy. Therefore, these dose levels (400 mg/kg/day for females; 500 
mg/kg/day for males) were considered to be the maximum tolerated 
doses (MTDs). Four additional, lower, dose levels were included in the 
main study. 
The EMS dose level (150 mg/kg/day) was selected based on previous 
usage as a positive control. Similar dosing regimens had historically 
resulted in no adverse clinical signs but resulted in significant MN and 
comet responses. 
4.5. Group allocation 
Animals were assigned to a dose group using a procedure that 
stratifies animals across groups by body weight such that mean body 
weight of each group was not statistically different from any other group 
using analysis of variance (ANOVA) (Statistical Analysis System version 
9.2, SAS Institute, Cary, NC). The group designations are shown in 
Supplementary Tables 3 and 4 
4.6. Dose preparation and administration 
2,6-Xylidine was prepared at ILS in corn oil at concentrations of 1.5, 
5, 10, 12.5, 20, 25, 40 and 50 mg/mL. Formulations were prepared once 
and stored at room temperature, protected from light, until used. Dose 
formulation samples were prepared and analysed at ILS in accordance 
with GLP regulations. Since 2,6-xylidine and the vehicle were miscible 
liquids, no homogeneity testing took place. At each dose level, 2 samples 
were collected on the day of preparation, one for immediate analysis and 
one to serve as a backup sample. The final diluted concentration of each 
sample fell within the analytical range of the method, namely each 
formulation was ±15% of nominal and a %RSD (Relative Standard 
Deviation) was ≤10.0%. 
The positive control, EMS, was prepared daily (room temperature, 
protected from light) at ILS in 0.9% saline at a concentration of 15 mg/ 
mL. 
Dose formulations were administered via oral gavage at a dose vol-
ume of 10 mL/kg body weight for 3 consecutive days at 0, 24 h (±30 
min) and 45 h (±30 min). Dose volumes were based on individual ani-
mal daily body weight. Dose formulations were placed on a stir plate at 
least 30 min prior to dosing and continuously stirred. The nasal tissue 
from the male rats (groups 1–6, Supplementary Table 3) were not frozen 
as per protocol and fresh animals were dosed to collect these tissues. 
4.7. Clinical observations 
Mortality/moribundity were checked twice daily on weekdays, once 
daily on weekends. Rats were observed within 2 days of arrival (for 
allocation of animals to dose groups), prior to daily administration, and 
(except TK groups 15–26) at termination. Cage-side observations were 
performed approximately 1 h after dose administration each day (groups 
1–14). Body weights were determined within 2 days of arrival (for 
allocation of animals to dose groups), prior to daily administration, and 
(except TK groups 15–26) at termination. 
4.8. Tissue sampling and processing 
At 3 h (±30 min) following the final dose administration the animals 
were humanely euthanized using C02 asphyxia confirmed by exsangui-
nation. Tissue sampling and processing for MN, comets, histopathology 
and bioanalysis followed standard methods, in accordance with GLP 
Regulations (40 CFR Part 160) and OECD guidelines TG474 (OECD, 
2016b) and TG489 (OECD, 2016c). Bioanalytical samples were pro-
cessed using HPLC/MS/MS (for 2,6-xylidine, conjugated-DMAP and 
glutathione) and GC/MS/MS (for DMHA) using validated procedures in 
accordance with FDA 2018 Guidance for Industry on Validation of 
Bioanalytical Methods. Blood and tissue sampling and processing 
methods are described in detail in Supplementary Document 2. Animal 
allocation to bioanalytic, and toxicokinetic groups, and reference stan-
dards used in analysis are shown in accompanying Supplementary Ta-
bles 3, 4 and 5, respectively. 
4.9. Statistical analysis 
Individual animal data and group means (with standard deviations) 
were calculated and reported. For final body weight, body weight gain 
(or loss) measurements, MN-PCE and PCE frequency data, and comets 
(% tail DNA), all data were analyzed using Statistical Analysis System 
version 9.2 (SAS Institute, Cary, NC). Homogeneity of variance was 
analyzed using Levene’s test and normality was assessed using the 
Shapiro-Wilk test on the control data. Homogenous data was then 
analyzed using a one-way analysis of variance (ANOVA), and test 
article-administered groups were compared to the appropriate control 
group using a one-tailed Dunnett’s test. Dose-dependent changes were 
evaluated using a linear regression model. Data that were not homo-
geneous and normally distributed were analyzed using the appropriate 
non-parametric one-tailed Dunn’s test. Dose-dependent changes were 
evaluated using an appropriate non-parametric trend test. Positive 
control data were analyzed by an appropriate t-test. P-values of <0.05 
were considered significant. 
4.10. Results 
4.10.1. Body weights, clinical observations and maximum tolerated dose 
Mean body weight changes are shown Table 1. It can be seen that 
there was a statistically significant and dose dependent decrease in final 
body weight, and therefore also in body weight gain, in male rats 
administered 2,6-xylidine. Males exposed to 250 and 500 mg/kg/day 
actually experienced significant body weight loss (4% and 7% respec-
tively over the 48 h of the study) compared to control animals, and this 
loss correlated strongly with dose (R2 = 0.9, p = 0.003). There was a 
statistically significant dose dependent linear trend for loss of weight in 
Table 1 
Summary of body weight changes.  




Initial Group Mean 
Body Weight (g) ±
SD 
Final Group Mean 
Body Weight (g) ±
SD 
Mean Body 
Weight Gain (g) 
± SDc 
0 274.60 ± 6.19 282.76 ± 8.34 7.1 ± 3.6 
15 270.56 ± 13.72 277.74 ± 8.43 4.5 ± 13.5 
50 276.92 ± 7.82 270.48 ± 7.48 − 3.0 ± 2.3 
125 271.66 ± 8.43 275.70 ± 7.02 2.2 ± 6.5 
250 271.12 ± 4.69 266.08 ± 11.90a ¡9.7 ± 6.2a 
500 275.30 ± 6.99 259.43 ± 4.51a b ¡19.7 ± 6.1a b 
EMS-150 274.84 ± 6.16 249.46 ± 7.77d ¡26.6 ± 3.4d 




Initial Group Mean 
Body Weight (g) ±
SD 
Final Group Mean 
Body Weight (g) ±
SD 
Mean Body 
Weight Gain (g) 
± SDc 
0 207.22 ± 7.88 209.20 ± 8.29 1.4 ± 3.2 
15 201.84 ± 5.92 206.10 ± 7.97 0.9 ± 3.2 
50 204.16 ± 6.60 200.74 ± 8.13 − 1.1 ± 7.5 
100 200.92 ± 9.03 199.06 ± 8.65 − 3.5 ± 6.3 
200 205.90 ± 4.51 201.86 ± 7.33 − 0.4 ± 3.8 
400 205.51 ± 7.43 197.00 ± 6.45 ¡6.0 ± 5.2b 
EMS-150 208.50 ± 5.63 187.96 ± 8.20d ¡22.7 ± 5.8d 
EMS = ethyl methanesulfonate. 
SD = standard deviation. 
a Statistically significant compared to the concurrent control mean (Dunnett’s 
test). 
b Dose dependent change (linear trend). 
c Calculated from individual animal data. 
d Statistically significant compared to the concurrent control mean (t-test). 
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female rats, however final body weight did not differ significantly from 
controls in any of the 2,6-xylidine treatment groups. 
The rapid (4–7.1%) body weight loss over 2 days in the male 250 and 
500 mg/kg/day groups approached the maximum limit of 10% body-
weight loss (BWL) for dosing over 7 days recommended to define the 
MTD for short-term rat toxicity studies (Chapman et al., 2013). These 
authors noted that a marked BWL which occurs over a shorter time 
period is less acceptable than the same BWL over a longer time period. A 
reason for this is that rapid weight loss may indicate significant dehy-
dration due to inappetence and/or fluid loss, which may be associated 
with a myriad of secondary physiological consequences. Chapman et al. 
(2013) proposed a decision tree for determination of MTD based on body 
weight loss and clinical factors, which, particularly if present in com-
bination, were a sign that the MTD had been reached, or even exceeded, 
and that a lower dose should be examined. 
Clinical signs were noted in all groups of male rats administered 2,6- 
xylidine, and in females at doses of 100, 200, and 400 mg/kg/day. Signs 
of toxicity were dose dependent and ranged from mild (rough coat), 
through to severe in the high dose groups, including decreased move-
ment, piloerection, ungroomed, uncoordinated movement, lethargy, 
cold to touch, rales, hunched, and abnormal breathing. In groups 1–14, 
all animals survived to the scheduled sacrifice (i.e. to 3 h after the last 
dose), however none of the male rats in the 500 mg/kg/day group in the 
TK part of the study survived to 24 h after the last dose. Based on these 
findings, the top dose of 500 mg/kg/day was considered to have 
exceeded the MTD for male rats in this study. Clinical effects were of 
lesser magnitude in male rats in the 250 mg/kg/day group than in rats 
dosed at 500 mg/kg/day, as they did not include breathing anomalies, 
and affected only 5 of 8 animals. In females dosed at 200 and 400 mg/ 
kg/day, 2/8, and 13/13 (respectively) exhibited behavioural abnor-
malities indicative of toxicity from mild-substantial degree. These data 
are considered to indicate that doses of 250 mg/kg/day in males and 
400 mg/kg/day in females met the OECD TG 489 criteria for an 
acceptable MTD for comet assay studies (OECD, 2016c). 
4.10.2. Micronucleus (MN) results 
Mean frequencies of bone marrow PCE and MN-PCE are presented in 
Table 2. MN-PCE frequencies in all vehicle control animals were within 
the laboratory’s historical negative control range (95% confidence in-
tervals are 0–0.31% for males and 0–0.28% for females). Administration 
of EMS, the positive control, resulted in statistically significant increase 
in % MN-PCE that clearly exceeded the historical negative control 
ranges, accompanied by significant decreases in % PCE, in both male 
and female rats. The study was therefore considered valid. It can be seen 
from Table 2 that no increases in the frequencies of MN-PCE were 
observed for male or female rats administered 2,6-xylidine, and all MN- 
PCE frequencies fell within the above-mentioned historical negative 
control ranges. Although there was a dose-dependent decrease in % MN- 
PCE and a significantly lower % MN-PCE in females exposed to 200 mg/ 
kg/day 2,6-xylidine, these changes are not considered to have any bio-
logical relevance. There was therefore no evidence of induction of MN in 
rat bone marrow of rats dosed with 2,6-xylidine up to, or above, the 
MTD. 
4.10.3. Comet results 
The group mean values for the % tail DNA for nasal tissue and liver of 
rats administered 2,6-xylidine or the positive control are shown in 
Table 3, and presented graphically in Figs. 3 and 4, together with 2,6- 
xylidine concentrations (see below). It should be noted that 2 animals 
(one male in the vehicle control group for nasal tissue, and 1 male in the 
15 mg/kg/day group for liver tissue) were removed from the calculation 
of means, and therefore excluded from further statistical analysis, as 
outliers (abnormally high % tail DNA values), and 1 female from the 
EMS group for nasal tissue was also excluded due to insufficient cells 
scored. 
For nasal tissue, the % tail DNA values for vehicle control animals 
exceeded the historical negative control ranges (95% confidence in-
tervals are 0–1.5% for males and 0–1.8% for females). However, the 
historical negative control data for rat nasal tissue was based on a very 
limited data set of only 5 animals. When compared with % tail DNA 
values in liver (see below) the concurrent vehicle control values ob-
tained in this study (see Table 3) are considered normal for a high turn- 
over tissue. Moreover, the positive control chemical (EMS) induced in-
creases in % tail DNA that were > 2× control values and significantly 
different. Thus, the comet evaluations in nasal tissue were considered 
valid. It can be seen from Table 3 and Fig. 3 that, although % tail DNA 
Table 2 
Summary of MN frequencies in rats administered 2,6-xylidine.  
A: Males 
Dose Level (mg/kg/ 
day) 
Mean % PCE ±
SEM 
Mean % MN-PCE ± SEM (4000 PCE/ 
animal scored) 
0 56.2 ± 0.7 0.12 ± 0.03 
15 57.8 ± 0.7 0.08 ± 0.02 
50 53.8 ± 1.7 0.13 ± 0.03 
125 55.4 ± 1.2 0.09 ± 0.03 
250 58.0 ± 0.8 0.09 ± 0.01 
500 54.6 ± 2.0 0.09 ± 0.01 
EMS-150 49.8 ± 0.2** 0.72 ± 0.06** 
B: Females 
Dose Level (mg/kg/ 
day) 
Mean % PCE ±
SEM 
Mean % MN-PCE ± SEM (4000 PCE/ 
animal scored) 
0 52.6 ± 1.7 0.14 ± 0.02 
15 57.4 ± 0.6 0.08 ± 0.01 
50 54.2 ± 1.6 0.09 ± 0.02 
100 54.8 ± 1.4 0.08 ± 0.03 
200 56.0 ± 1.4 0.05 ± 0.02* 
400 54.2 ± 2.1 0.07 ± 0.02a 
EMS-150 46.2 ± 1.1** 0.51 ± 0.08** 
EMS = ethyl methanesulfonate. 
MN-PCE = micronucleated polychromatic erythrocytes. 
SEM = standard error of the mean. 
*Statistically significant compared to the concurrent control mean (Dunnett’s 
test). 
**Statistically significant compared to the concurrent control mean (t-test). 
a Dose dependent change (downward linear trend). 
Table 3 
Summary of comet assay results in liver and nasal tissue.  
A: Males 
Dose Level (mg/kg/day) Liver 
Mean % Tail DNA ± SEM 
Nasal 
Mean % Tail DNA ± SEM 
0 1.44 ± 0.31 4.59 ± 2.43b 
15 1.15 ± 0.20b 5.59 ± 2.19 
50 3.42 ± 1.60 5.62 ± 1.35 
125 2.60 ± 0.90 7.45 ± 3.08 
250 4.32 ± 1.10 6.70 ± 1.59 
500 4.59 ± 1.15a 8.35 ± 1.37 
EMS-150 20.76 ± 1.25* 17.13 ± 1.16* 
B: Females 
Dose Level (mg/kg/day) Liver 
Mean % Tail DNA ± SEM 
Nasal 
Mean % Tail DNA ± SEM 
0 2.03 ± 0.69 3.81 ± 1.24 
15 1.74 ± 0.42 1.41 ± 0.43 
50 1.55 ± 0.70 2.03 ± 0.92 
100 2.09 ± 0.30 1.07 ± 0.50 
200 1.79 ± 0.41 4.58 ± 2.76 
400 2.10 ± 0.49 2.31 ± 0.54 
EMS-150 14.83 ± 1.24* 7.74 ± 1.07*b 
EMS = ethyl methanesulfonate. 
SEM = standard error of the mean. 
*Statistically significant compared to the concurrent vehicle control (t-test). 
a Dose dependent change (upward linear trend). 
b Based on 4 animals – see text for details. 
D.J. Kirkland et al.                                                                                                                                                                                                                             
Regulatory Toxicology and Pharmacology 119 (2021) 104838
12
values exceeded the very limited historical negative control range, there 
were no significant increases in % tail DNA as compared with the con-
current vehicle control groups in either female or male rats exposed to 
2,6-xylidine. It was therefore concluded that 2,6-xylidine did not induce 
DNA damage in nasal tissue of rats, dosed up to, or above, the MTD. 
For liver tissue, the % tail DNA values for vehicle control animals all 
fell within the historical negative control ranges (95% confidence in-
tervals for the most recent studies are 0–8.8% for males and 0–7.2% for 
females), and the positive control chemical (EMS) induced significant 
increases in % tail DNA. Thus, the comet evaluations in liver tissue were 
considered valid. It can be seen from Table 3 and Fig. 4 that there were 
no significant increases in % tail DNA in either female or male rats 
Fig. 3. Comet responses and 2,6-xylidine levels in nasal tissue.  
D.J. Kirkland et al.                                                                                                                                                                                                                             
Regulatory Toxicology and Pharmacology 119 (2021) 104838
13
Fig. 4. Comet responses and 2,6-xylidine, DMHA and DMAP levels in liver.  
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exposed to 2,6-xylidine as compared with concurrent controls, all values 
were within the historical negative control range, and below the OECD 
recommended limit of 6% for hepatic tissues (OECD, 2016c). In male rat 
livers however, there was a low magnitude but statistically significant 
dose response. It was therefore concluded that 2,6-xylidine did not 
induce DNA damage in livers of female rats, but there was an equivocal 
response in livers of male rats. 
Fig. 5 shows that there was a strong correlation between dose, weight 
loss and comet responses in male rat liver. Additional analyses were 
therefore performed on the comet dose response findings in male liver 
and potential for co-linearity with weight loss. This identified (Fig. 6) 
that there was a strong correlation between weight loss in male rats and 
comet values in male liver (R2 = 0.85, p = 0.008). Weight loss rather 
than dose provided the stronger correlation with comet values using 
multiple linear regression. There was no significant dose response trend 
if results from animals suffering acute toxicity with significant weight 
loss (i.e. the 250 and 500 mg/kg/day groups) were excluded from the 
analysis. Therefore, in male rats dosed up to and including 125 mg/kg/ 
Fig. 5. % Tail DNA for male rat livers versus weight gain/loss. Treatment groups showing the greatest numeric increase above negative control values were also 
those that exhibited the greatest weight loss. 
Fig. 6. Correlation between comets (%tail DNA) in liver and weight loss in male 2,6-xylidine treated rats - line fit plot.  
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day, the comet results in liver met all 3 criteria for a clearly negative 
result as specified by OECD (OECD, 2016c), namely not significantly 
different from concurrent controls, within the historical negative control 
range, and no dose response. 
4.10.4. Bioanalysis 
Group mean 2,6-xylidine concentrations in plasma, liver and nasal 
tissue sampled at sacrifice for the comet/MN analyses (i.e. 3 hrs. after 
the final dose) are presented in Table 4. At 15 mg/kg/day 2,6-xylidine 
concentrations were below the limits of quantitation in plasma and 
nasal tissue of female rats, however it was detectable in the liver of both 
sexes and nasal tissue of males. At dose levels of 50–500 mg/kg/day, 
2,6-xylidine was detectable in plasma, liver and nasal tissue of all rats 
(male and female), and increased in a dose-responsive manner. These 
data confirm systemic, as well as nasal and hepatic tissue exposure to 
2,6-xylidine in male and female rats. 
Group mean data for 2,6-xylidine concentrations in plasma for the 
TK timepoints are presented for males in Table 5. The plasma levels of 
2,6-xylidine increased in a dose-dependent manner in both sexes for 
each timepoint except for the 24-h timepoint at which all samples were 
below the limit of quantitation. Additionally, the lowest dose level (15 
mg/kg/day) was below the limit of quantitation with the exception of a 
single male at the 1-h timepoint. Since the bone marrow is a well- 
perfused tissue, these data also confirm systemic (and therefore bone 
marrow) exposure to 2,6-xylidine in male and female rats. 
4.10.5. Additional analyses of male rat liver 
Based on the “equivocal” result from a positive trend test for comets 
in the male liver, additional analyses for concentrations of DMHA, 
DMAP-conjugate and glutathione were performed on male liver tissue 
only, to investigate metabolic parameters and indications of oxidative 
stress. The data are tabulated in Table 6, and presented graphically for 
DMAP-conjugate and DMHA in Fig. 3. DMAP-conjugate was detectable 
at 15 mg/kg/day and increased with dose up to 250 mg/kg/day, with 
Table 4 
Summary of 2,6-xylidine concentrations in plasma and tissues sampled 3 h after 



























































67960.0 ± 27940.0  
B: Females 
Dose Level (mg/ 
kg/day) 




0 LLOQ (<500) LLOQ (<2000) LLOQ (<1000) 
15 1403.2 ± 1411.6a LLOQ (<2000) LLOQ (<1000) 
50 6792.0 ± 2418.1 3050.0 ± NAb a 3292.0 ± 811.3 
100 23060.0 ± 3431.2 5880.0 ±
6157.0a 












LLOQ = lower limit of quantitation. 
SD = standard deviation. 
a Calculated from individual animal data using the LOQ value for values <
LLOQ. 
b Data from a single animal above the LOQ. 
Table 5 



































































































































































SD = standard deviation. 
LLOQ = lower limit of quantitation. 
a Calculated from individual animal data using data above the limit of 
detection. 
b Data from a single animal above the limit of detection. 
c No males survived in this group to 24 h post dose. 
Table 6 
Summary of DMAP-conjugate, DMHA, and glutathione concentrations in male 








g) ± SD 
0 LLOQ (<200) LLOQ (<50) 607400.0 ±
126638.5 
1 308.0 ± 95.3 LLOQ (<50) 646400.0 ±
129666.1 
50 555.0 ± 234.5 LLOQ (<50) 831600.0 ±
105632.9 




250 18920.0 ± 4680.5 671.0 ± 382.7 764800.0 ±
183626.5 




SD = standard deviation. 
LLOQ = lower limit of quantitation. 
a Calculated from individual animal data using the LLOQ value for values <
LLOQ. 
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the levels exhibiting similar levels (i.e. a plateau) at 250 and 500 mg/kg/ 
day, suggesting that 4-hydroxylation of 2,6-xylidine became saturated in 
male rat liver at doses >125 mg/kg/day. DMHA was not detectable in 
quantifiable levels in rats dosed at 15 or 50 mg/kg/day, but was present 
in relatively minor, but increasing concentrations in rats dosed at 
125–500 mg/kg/day. Therefore, male rat livers were exposed to DMHA 
and DMAP at doses that did not lead to increased comets. Glutathione 
levels were not significantly different from vehicle control levels in any 
of the 2,6-xylidine-dosed groups. 
4.10.5.1. Histopathology male rat liver. When liver samples were eval-
uated for histopathology, microscopic findings were evident in the 500 
mg/kg/day group including minimal increases in centrilobular hepato-
cellular hypertrophy (3/5 animals), diffuse periportal hepatocellular 
vacuolation (2/5 animals), the number of hepatocellular mitoses (2/5 
animals) and inflammation (1 animal). A minimal increase in periportal 
hepatocellular vacuolation and mitosis was also seen in 1/3 animals 
treated at 250 mg/kg/day, but not in any animals treated at lower doses. 
4.10.5.2. Benchmark dose analysis of comet response in male rat liver. 
Benchmark dose analysis was also conducted using the weak dose 
response in comet % tail DNA in male rat liver tissue. The benchmark 
dose (BMD) approach is considered the most suitable for use in calcu-
lating point of departure (PoD) metrics from continuous genetic toxicity 
data, and is more conservative than measures such as no-observed 
genotoxic effect level (NOGEL) or slope transition dose (Johnson 
et al., 2014; MacGregor et al., 2015). It has been recently shown that a 
critical effect size (CES) of 50% is suitable for use in calculating BMD 
confidence intervals (BMD CI) (Zeller et al., 2017). Furthermore, 
increased precision in the BMD confidence interval (CI) calculation can 
be obtained by using the covariate BMD approach (Slob and Setzer, 
2014; Wills et al., 2016). The BMDL50 is considered the most appro-
priately conservative PoD metric for use in defining human exposure 
limits. It should be noted that since the comet assay detects early events, 
it is therefore more conservative as an endpoint, and usually provides 
lower PoDs, than intermediate and apical endpoints such as chromo-
somal aberrations, micronuclei or gene mutations. 
BMD analysis was conducted using PROAST, the dose–response 
modelling software developed at the National Institute for Public Health 
and the Environment (RIVM) in the Netherlands [http://www.proast.nl; 
version 65.5] (Slob, 2002). The default assumptions from PROAST were 
used for the BMD analysis. The nested set of models used included the 
non-linear exponential and Hill models that are recommended by the 
European Food Safety Authority (EFSA, 2009). The CES 50% was used to 
define the BMD values and the lowest BMD50 and BMDL50 from both 
models are included in Table 7, along with the highest BMDU50. Due to 
the weak dose response in the in vivo liver comet data, standard BMD 
analysis showed no dose response, therefore increased precision was 
required through the covariate BMD approach, as described by Wills 
et al. (2016), using liver comet data from 2 structural related chemicals, 
o-anisidine and p-chloroaniline which had been tested using a similar 
protocol. Using this approach, the Hill and exponential models provided 
a suitable fit with 2,6-xylidine and showed the liver comet response was 
non-linear. The BMDL50 metric for comet was calculated to be 97 
mg/kg/day (Table 7), i.e. lower than NOGEL of 125 mg/kg/day, as 
expected. Detailed data and the BMD modelling are shown in Table 8 
and Fig. 7. 
4.11. Discussion of new MN/comet study results 
4.11.1. Metabolic and toxicokinetic findings 
Administered at a dose of 15 mg/kg/day, to rats, 2,6-xylidine was 
present in quantifiable levels in hepatic tissue, but not quantifiable in 
plasma or nasal tissue in the majority of rats in this study. This suggests 
that, at this dose, it is efficiently cleared via intrahepatic metabolism, 
consistent with findings previously reported by Lindstrom et al. (1963). 
These authors investigated 2,6-xylidine metabolism and elimination in 
Osborne-Mendel rats, and reported that at low doses (up to 50 ppm in 
feed) 2,6-xylidine was virtually completely metabolised, with little un-
metabolized 2,6-xylidine detectable in urine. Over 90% of the dose was 
recovered in urine as conjugated-DMAP, with small amounts of unme-
tabolized 2,6-xylidine and no other metabolites detected. This study 
identified 4-hydroxylation as the major pathway of metabolism and 
elimination of 2,6-xylidine in vivo in rats, which is further confirmed by 
our finding of conjugated-DMAP, but not DMHA in livers of male rats 
dosed at 15–50 mg/kg/day in the current study. Additionally, we did not 
find evidence of clinical toxicity in male or female rats, nor hepatotox-
icity in male rats dosed at these levels, consistent with previous reports 
identifying 20 mg/kg/day as a NO(A)EL for repeated dose toxic effects 
of 2,6-xylidine in CD rats (NTP 1990). Yasuhara et al. (2000) similarly 
reported that 2,6-xylidine was below levels of detection in plasma, and 
did not induce cytotoxic effects in nasal tissue based on histopatholog-
ical analysis, when fed to rats at doses of 300 ppm in diet (estimated 
Table 7 
BMD confidence intervals for male rat liver comet results (% tail DNA).   
p-chloroaniline (mg/kg) 2,6-xylidine (mg/ 
kg) 
o-anisidine (mg/kg) 
BMD50 36 322 391 
BMDL50 11 97 141 
BMDU50 54 512 572 
The values are calculated from BMD modelling shown in Fig. 7 (raw data shown 
in Table 8). The lowest BMD50 and BMDL50, and the highest BMDU50 from the 
non-linear exponential and Hill models, are presented. 
p-chloroaniline data from Barfield and Burlinson (2015). 
o-anisidine data from Hobbs et al. (2015). 
Table 8 
Summary of % tail DNA data in rat liver for 2,6-xylidine and the 2 related 
substances used for covariate analysis. In each case n = 5. SEM = standard error 




% Tail DNA; 
mean of 
medians 
% Tail DNA: 





0 1.44 0.31 2,6-xylidine Current ILS 
study 
15 1.15 0.2 2,6-xylidine Current ILS 
study 
50 3.42 1.6 2,6-xylidine Current ILS 
study 
125 2.6 0.9 2,6-xylidine Current ILS 
study 
250 4.32 1.1 2,6-xylidine Current ILS 
study 
500 4.59 1.15 2,6-xylidine Current ILS 
study 
0 0.3 0.06 o-anisidine Hobbs et al. 
(2015) 
150 0.4 0.11 o-anisidine Hobbs et al. 
(2015) 
300 0.4 0.15 o-anisidine Hobbs et al. 
(2015) 
600 0.9 0.22 o-anisidine Hobbs et al. 
(2015) 
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intake 27 mg/kg/day) for one week. Together these data support the 
conclusion that when administered at doses up to 15–20 mg/kg/day, 2, 
6-xylidine is effectively detoxified via 4-hydroxylation and phase 2 
metabolism, and eliminated in the urine without pathological effect. 
Higher doses appear to be associated with saturation of 4-hydroxyl-
ation, disturbed metabolism and onset of systemic toxic effects. 
Administered at higher doses to rats in the most recent study (described 
above), 2,6-xylidine became detectable in plasma and nasal tissues (as 
well as liver), and increased in a dose dependent manner. DMAP- 
conjugate concentrations in the livers of male rats appeared to satu-
rate at doses >125 mg/kg/day. This was associated with the onset of 
clinical signs indicative of systemic toxicity, including significant weight 
loss of 4–7%, which also became evident in male rats at doses >125 mg/ 
kg/day. These findings are also consistent with previous reports. Lind-
strom et al. (1963) reported that at high doses (200 mg/kg/day by 
gavage for 8 days), in addition to conjugated-DMAP, unmetabolized 2, 
6-xylidine appeared in the urine in significant amounts indicating 
saturation of metabolic clearance via 4-hydroxylation. Discolouration of 
the urine was noted following 8 days of dosing, considered to be 
indicative of significant disturbance of normal metabolism. In addition 
to conjugated-DMAP and 2,6-xylidine, trace amounts of 2-AMBA were 
detected in urine, suggesting that low level metabolism may occur via 
alternative pathways at these high dose levels. Hardy (1986), and Short 
et al., 1989a reported similarly. These authors used Gas Chromatog-
raphy (GC) and GC/Mass Spectrometry to examine urinary metabolites 
in male Fischer 344 rats administered 2,6-xylidine by gavage at 262.5 
mg/kg/day for one or 10 days. DMAP-conjugate was the predominant 
urinary metabolite identified in urine, constituting up to 66% of the dose 
with the bulk of the remainder (up to 33%) excreted unmetabolized. 
Trace levels of N-2,6-trimethylaniline were detected (<LOQ), however 
no other metabolites were present in detectable level; metabolites for 
which standards were prepared, but which were not detected included; 
Fig. 7. BMD50 outputs (PROAST v67) defined for % tail DNA dose response data from male rat livers exposed to 2,6-xylidine.  
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DMHA, N-acetyl-2,6-DMA, 2,6-dimethyl-nitrobenzene and 2-AMBA. 
N-oxidation (to DMHA) has, however, been identified as a very 
minor intra-hepatic pathway of metabolism, (evident only following 
high doses of 125 mg/kg/day and above) in male rats in the current 
study. This finding is in contrast to Lindstrom et al. (1963) and Hardy 
(1986) who did not identify DMHA (or other N-oxidised metabolites) in 
urine of rats. It is, however, consistent with in vitro reports. Kirkland 
et al. (2012) detected DMHA as a minor metabolite of 2,6-xylidine in 
vitro using high concentrations of 2,6-xylidine incubated with rat he-
patic microsomes. The reaction had a Km of 45 and Vmax of 0.04, 
indicative of very low production. Gan et al. (2001) examined 2,6-xyli-
dine metabolism following incubation with human hepatic microsomes. 
Low level DMHA production (constituting 2–3% of metabolic product) 
was detected following incubation with 2,6-xylidine at nanomolar 
concentrations (however DMAP was the only metabolite present 
following incubation with 2,6-xylidine at higher concentrations). These 
authors furthermore reported that, when present, DMHA was rapidly 
re-arranged to DMAP via Bamberger arrangement; rapid re-arrangement 
of DMHA to DMAP, could explain why DMHA is detectable in hepatic 
tissue, but not in rat urine in vivo. 
Together these findings are considered to support the conclusions of 
previous authors that, by virtue of the two methyl groups either side of 
the amine moiety, 2,6-xylidine is highly resistant to N-hydroxylation 
and preferentially metabolised via 4-hydroxylation and phase 2 conju-
gation. At oral doses <15–20 mg/kg/day it is rapidly and extensively 
metabolised via this process and eliminated in urine without patholog-
ical effect. At doses >125 mg/kg/day however, there is evidence of 
metabolic overload with saturation of production of conjugated-DMAP 
associated with acute systemic toxic effects. DMHA appears to be a 
minor intermediate intrahepatic metabolite in vivo in male Sprague- 
Dawley rats only following high dose oral 2,6-xylidine administration. 
4.11.2. Clinical and toxicological findings 
In this study, mild clinical signs of toxicity became evident at a dose 
of 50 mg/kg/day and increased in severity with dose, such that all rats in 
high dose male and female groups displayed signs of moderate to severe 
toxicity, including reduced and/or uncoordinated movement, and rales 
or moderate to severe abnormalities of breathing. Weight loss was also a 
feature. This was particularly evident in male rats dosed at 250 and 500 
mg/kg/day, where 4 and 7% bodyweight loss (respectively) occurred 
over the 48 h of the study, and thus 500 mg/kg/day was determined to 
have exceeded the MTD for this study. 
Clinical findings in the current study concorded with previous pub-
lished reports of acute and repeated dose systemic toxic effects of 2,6- 
xylidine in rats. These findings identified weight loss, lethargy, 
cyanosis, breathing abnormalities, and circulatory collapse as acute 
toxic effects. On bioanalysis, haemolysis and met-Hb formation, high 
urine output with low urinary specific gravity (indicative of diuresis) 
along with renal and hepato-toxicity were reported. In addition, male 
rats are reported to be more sensitive to acute systemic toxicity than 
female rats (Jacobson, 1983; SIDS, 2012; NTP, 1990). 
It is notable that the acute systemic toxic effects of 2,6-xylidine are 
likely to be associated with ROS production, oxidative stress and/or 
oxidative DNA injury as have been reported in other settings, thereby 
potentially confounding assessment of in vivo genotoxicity. Rapid weight 
loss, for example, is generally indicative of acute dehydration due to 
inappetence and/or fluid loss. Dehydration results in reduced tissue 
perfusion and tissue anoxia resulting in oxidative stress (França et al., 
2007). Dehydration resulting in loss of 3% bodyweight in human vol-
unteers, for example, has been shown to induce oxidative stress, as 
evidenced by a statistically significant increase in malondialdehyde 
(MDA) levels, total antioxidant status (TAS), and DNA damage as 
assessed via lymphocyte comet assay (Paik et al., 2009). Similarly, rales 
and breathing anomalies may signify the presence of hypoxia. Para-
doxically, hypoxic cells increase their mitochondrial production of 
reactive oxygen species (ROS) leading to oxidative stress. High levels of 
lipid, protein, and DNA oxidative damage have been measured in 
humans after exposure to hypoxia (Møller et al., 2001). Similarly, 
met-Hb impedes tissue oxygen transfer, contributing to tissue hypoxia, 
and has been shown to induce oxidative stress and related DNA injury 
(Albuquerque et al., 2015). Although similar studies are not available in 
rats, these data identify the potential for the observations in in vivo 
genotoxicity tests to be confounded by systemic toxicity-induced 
oxidative stress. In vivo, oxidative stress may be short-lived, and/or 
oxidative damage may be rapidly repaired. The comet assay is a highly 
sensitive marker of DNA injury and repair (Speit and Rothfuss, 2012), 
and may be more sensitive to short-lived oxidative stress than other 
markers such as 8-OH-dG and MN (Hartmann et al., 1998). Systemic 
toxic effects such as these are thus more likely to influence an “indica-
tor” endpoint such as comets than an “apical” endpoint such as MN. 
4.11.3. Micronucleus study findings 
In the current study, there was no evidence of a genotoxic response to 
2,6-xylidine in vivo based on MN findings in rats dosed up to (females) 
and above (males) the MTD. Systemic 2,6-xylidine exposure (plasma and 
tissues) was clearly evident. These data support previous negative MN 
findings in bone marrow and in peripheral blood of mice. 
4.11.4. Comet study findings 
In the current study, there was no evidence of a genotoxic response to 
2,6-xylidine in rat nasal tissues or hepatic tissue of female rats when 
dosed up to the MTD, or in male rats at non-toxic doses (i.e. up to 125 
mg/kg/day), based on comet results. 
In male rat hepatic tissue an “equivocal” response was evident which 
prompted further investigation. The equivocal response was recorded by 
virtue of finding a low magnitude positive dose response, although all % 
tail DNA levels fell well within historical control ranges (<8.8% tail 
DNA), as well as below the OECD recommended upper limit of 6% 
(OECD, 2016c), and none were significantly different from concurrent 
controls. Results from all treatment groups were therefore within the 
normal variability of the test. 
The low magnitude dose response was driven both by low % tail DNA 
values for male liver in the vehicle control and 15 mg/kg/groups, and by 
a relative increase in % tail DNA in the 250 and 500 mg/kg/day groups. 
Higher doses of 2,6-xylidine were administered to male than female rats 
in the high dose groups, however hepatic tissue concentrations were 
comparable (see Table 4), such that this did not explain the relative 
increase in comets in the hepatic tissue of male rats. Male rats did, 
however, exhibit greater systemic toxicity (including weight loss) than 
female rats. Systemic toxic effects in male rats dosed at 250 and 500 mg/ 
kg/day were such as may have induced oxidative stress (such as sec-
ondary to dehydration and/or tissue hypoxia, as detailed above), 
potentially impacting comet results. In support of this, there was strong 
co-linearity between weight loss and dose, and weight loss rather than 
dose showed the stronger correlation with % tail DNA response in he-
patic tissue in male rats (see Fig. 6). Bioanalysis also revealed evidence 
of saturation of 4-hydroxylation (the normal pathway of metabolic 
detoxification an elimination) in hepatic tissue of male rats at doses >
125 mg/kg/day. Glutathione levels however were not depleted 
(Table 6). This would argue against high levels of DMQI production and 
suggest that a threshold for significant ROS production secondary to 
redox cycling of DMQI (if present) was not reached prior to the onset of 
acute systemic toxicity. In addition, there was evidence of early hepa-
totoxicity in male rats in these two groups. 
The nature of histopathological findings are probably not sufficiently 
severe to indicate that comets in male rat liver were increased as an 
indirect consequence of frank liver cytotoxicity, however, as noted in the 
JaCVAM validation trial (OECD, 2014) “no definitive list of histopath-
ological changes that are always associated with increased DNA 
migration is available and increased comet values in the presence of 
histopathological changes should be interpreted with caution and may 
warrant repeating the assay at lower doses”. Moreover, it should be 
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considered that more severe histopathological changes to liver may have 
been seen at later sampling times, and that only 2 days after the start of 
dosing may have been too early to observe such changes. 
The equivocal dose response was therefore potentially impacted by 
the presence of metabolic overload and excessive systemic toxicity in 
rats dosed at 250 and 500 mg/kg/day, (the latter of which is considered 
to have exceeded the MTD for this trial). OECD guideline 489 (OECD, 
2016c) recommends dose levels used for both acute and sub-acute ver-
sions of the comet assay should cover a range from the maximum to one 
producing little or no toxicity. In this study, a range of lower doses 
(15–125 mg/kg/day) were used that did not induce significant systemic 
toxicity, weight loss, or hepatotoxicity in male rats. Examined over this 
(“non-toxic”) dose range, there was no significant dose response and the 
comet results in male rat liver were clearly negative. Additionally, 2, 
6-xylidine, DMAP-conjugate and DMHA were present in hepatic tissue 
over this dose range (see Fig. 3 and Tables 4 and 6), such that lack of 
exposure to 2,6-xylidine or metabolites is not an explanation of lack of 
genotoxic response at “non-toxic” doses. 
Therefore, there was no clear indication of biologically relevant 
genotoxic activity in male or female rats at doses up to those inducing 
significant weight loss or signs of acute systemic toxicity, which in fe-
males was 400 mg/kg/day, and in males was 125 mg/kg/day. The male 
liver comet dose response result may therefore be considered not bio-
logically relevant (all data within historical control range) or it may be 
considered that there is a threshold defined by acute systemic toxicity. 
Since there was no induction either for MN in bone marrow, or comets in 
nasal tissue or liver, at acceptable levels of toxicity, the no-effect doses 
are concluded to be 125 mg/kg/day in males and 400 mg/kg/day in 
females. 
These results are considered to highlight the importance of using a 
range of doses for comet assay studies that include doses that produce 
little or no toxicity in accordance with OECD guidance GL 489. Previous 
studies testing 2,6-xylidine for induction of DNA strand breaks via the 
comet assay in mice (Kohara et al., 2018; Sasaki et al., 1999 above) 
reported increased comets in various tissues, but the sampling times and 
tissues affected were inconsistent across the 2 studies. Moreover, both 
these investigators used only a single dose level (200 mg/kg and 350 
mg/kg via gavage respectively). These doses were thus similar to, or 
exceeded, dose levels which induced metabolic overload, significant 
weight loss and systemic toxic effects in rats in the current study. There 
are currently no data regarding 2,6-xylidine metabolism, nor the nature 
of acute toxic effects in mice, however the LD50 of 2,6-xylidine in mice 
(710 mg/kg), is well below that reported in rats (1230 mg/kg; Vernot 
et al., 1977), suggesting that mice may be more sensitive to 2,6-xylidine 
toxicity than rats. Neither authors reported on body weight or other 
clinical effects, however Sasaki et al. (1999) did report evidence of urine 
discoloration in mice. This is also reported as an acute toxic effect in rats 
associated with disturbed normal metabolism, met-Hb formation and 
haemolysis (NTP, 1990; Lindstrom et al., 1969). It is therefore possible 
that systemic toxic effects may have contributed to comet results in mice 
in these studies. 
5. Overall discussion of published and new data 
5.1. 2,6-Xylidine carcinogenicity: mechanistic considerations 
A possible mode of action for rat nasal tumours induced by 2,6-xyli-
dine (NTP, 1990) is one in which large 2,6-xylidine dietary exposures 
overwhelm normal hepatic metabolism and detoxification (via 4-hy-
droxylation and conjugation) delivering high concentrations of 2,6-xyli-
dine via the systemic circulation to nasal tissue, which is known to have 
high metabolic capacity (Yasuhara et al., 2000; Koujitani et al., 1999, 
2001). One hypothesis is that it may then be metabolised via N-hy-
droxylation, resulting in DMHA formation and genotoxicity via DNA 
adduct formation. According to current thinking, unless a specific DNA 
repair pathway can be shown to produce a threshold, this would be a 
non-threshold mechanism. An alternative hypothesis is that it may be 
metabolised to DMAP with potential to undergo threshold-affected 
metabolic activation to DMQI. In this situation, cytotoxicity and geno-
toxicity secondary to DMQI redox cycling and ROS production would be 
expected only if present in concentrations sufficient to overwhelm phase 
2 conjugation of DMAP and glutathione detoxification of DMQI. Addi-
tionally, in vivo, anti-oxidant defence mechanisms exist to prevent, 
and/or rapidly repair oxidative DNA injury (Davies, 2001; Lan et al., 
2004) such that any cytotoxic and/or genotoxic effects resulting from 
ROS production may also exhibit a threshold. 
The metabolism of 2,6-xylidine in rat nasal tissue has not been 
studied, however the metabolism of 2,6-diethylaniline (a close struc-
tural analogue that also induces nasal tumours in rats) has been exten-
sively studied. These studies have identified that 4-hydroxylation of the 
2,6-dialkylalinine (forming 2,6-diethyl-aminophenol) occurs at a 7- fold 
greater rate in rat nasal tissue as compared with the liver, due to a high 
concentration of site- and species-specific p450 CYP2A3 (Feng et al., 
1990; Green et al., 2000). Detoxifying enzymes important in 2,6-xyli-
dine metabolism (including UTP-glucuronide transferase, and organic 
sulphates/PAS sulphatases, GSH and GSH-transferase), although present 
in rat nasal tissue, are, however, at lower levels than in the liver in 
Sprague Dawley rats (Longo et al., 1988; Heydens et al., 1999). This, (in 
conjunction with the relatively high pO2 environment), predisposes to 
quinone-imine formation in rat nasal tissues. Quinone-imine protein and 
glutathione thioether binding result in nasal tissue persistence, and (at 
high production levels), cytotoxicity and a proliferative response (ROS 
production has not been measured). This is considered the primary 
mechanism predisposing to 2,6-diethylaniline tumour formation in the 
nasal tissue of rats (Heydens et al., 1999). It should be noted that 2, 
6-diethylaniline does not undergo N-oxidation in rat hepatic or nasal 
tissue, consistent with the postulate that alkyl groups in the 2,6-position 
impede N-hydroxylation of dialkylanilines (Feng et al., 1990; Green 
et al., 2000). These findings are highly consistent with, and similar to 
those of Tydén (2004), who reported tissue persistence of 2,6-xylidine 
24 h post administration in rats occurs most prominently in olfactory 
tissue and Bowman’s glands, and is associated with a markedly 
increased capacity of rat olfactory tissue to activate 2,6-xylidine to a 
protein-binding metabolite in vitro, occurring at a rate 5–12 times 
greater than other tissues including hepatic tissue. Together these data 
suggest that intra-nasal metabolic activation of 2,6-xylidine may occur 
secondary to excessive production of DMAP, (sufficient to overwhelm 
phase 2 metabolism and result in DMQI-formation) rather than pro-
duction of DMHA and activation to nitrenium ions as previously 
presumed. 
To further investigate these hypotheses, it was intended in the cur-
rent study to undertake assessment of DMAP, DMHA, glutathione and 8- 
OH-dG levels in tissues exhibiting clearly positive genotoxicity. In the 
event, however, there was no evidence of clearly positive genotoxicity in 
any of the tissues. Additional investigations were therefore undertaken 
only in male rat hepatic tissue by virtue of finding an equivocal comet 
response in this tissue. Nevertheless, some observations can be made, as 
discussed below. 
5.2. Nasal tissue findings 
In overview, results of the current study are considered to support 
the conclusion that at low doses (15–20 mg/kg/day), 2,6-xylidine is 
efficiently cleared by hepatic metabolism so that there is negligible 
systemic or nasal tissue bioavailability such as to induce toxic, cytotoxic 
or genotoxic effects. Despite being detectable in liver, 2,6-xylidine 
concentrations were below quantifiable levels in nasal tissue in the 
majority of rats administered 2,6-xylidine at 15 mg/kg/day in this study, 
and there was no increase in comet levels. Yasuhara et al. (2000) pre-
viously documented lack of nasal cytotoxicity, and undetectable levels 
of 2,6-xylidine in plasma of rats fed doses of 30 ppm in diet for 1 week 
(estimated intake 26 mg/kg/day). It is notable as well, that there was no 
D.J. Kirkland et al.                                                                                                                                                                                                                             
Regulatory Toxicology and Pharmacology 119 (2021) 104838
20
significant increase in nasal, or other tumours in rats fed 15 mg/kg/day 
2,6-xylidine in the NTP (1990) rat carcinogenicity study. 
At higher doses, 2,6-xylidine is bioavailable in nasal tissues in both 
male and female rats. Despite this finding however, we did not find 
evidence of any biologically relevant DNA damage in rat nasal tissue in 
this study. This argues against any direct genotoxic mechanism of action 
of 2,6-xylidine in nasal tissue (such as due to N-hydroxylation to DHMA, 
with nitrenium ion and mutagenic DNA adduct formation). It also sug-
gests that if 2,6-xylidine induces DNA damage via a threshold mecha-
nism, (such as due to DMAP-DMQI redox cycling and ROS-related 
oxidation injury) that such a threshold (sufficient to overwhelm nasal 
phase 2 metabolism and anti-oxidant capacity) was not reached. This 
does not preclude the possibility, however, that such a threshold may be 
reached with more prolonged dosing at levels sufficient to deplete phase 
2 metabolites, glutathione and/or anti-oxidant capacity over time. 
Yasuhara et al. (2000) reported that cytotoxicity became evident in rat 
nasal tissue, particularly in Bowmans glands, following 4 weeks 
administration of 2,6-xylidine at doses of 256.2 mg/kg/day. 
5.3. Role of oxidative injury secondary to DMAP-DMQI redox cycling 
The low magnitude increase in comets seen in the current study in 
hepatic tissue of male rats exhibiting acute systemic toxicity, was not 
associated with glutathione depletion. This suggests that DMQI and ROS 
could only have been formed (if at all) at low concentrations, insufficient 
to overwhelm anti-oxidant capacity, which is consistent with lack of 
clearly positive comet results. Furthermore, any potential effect of low- 
grade oxidative stress on comet results via this mechanism would be 
difficult to distinguish from that potentially induced secondary to acute 
systemic effects such as dehydration, met-Hb and/or tissue hypoxia, 
which, amongst other factors, may directly impact production of ROS, 
(França et al., 2007; Pastukh et al., 2015). In the absence of clearly 
positive comet responses there was no point to measure markers of 
oxidative DNA damage (such as 8-OH-dG) since levels of this marker 
would also be expected to be within the normal range. Overall, results of 
this study are taken to indicate that acute systemic toxicity occurs prior 
to a threshold for glutathione depletion and the potential for oxidative 
DNA injury secondary to DMAP-DMQI-redox cycling in rats. 
5.4. Implications for role of DMHA 
In the current study we have shown there is minor intrahepatic 
DMHA production in vivo in male Sprague-Dawley rats fed high doses of 
2,6-xylidine of 125 mg/kg/day or greater. It is noted however that (in 
the absence of weight loss and systemic toxicity) DMHA production was 
not associated with a significant increase in comet levels above con-
current or historical control values such as in male rats fed 125 mg/kg/ 
day, suggesting lack of direct association with genotoxicity. This is 
consistent with findings reported by Kirkland et al. (2012) who did not 
find evidence of a positive response in the Ames test using rat liver S9 
despite biological DMHA production. This is considered to further argue 
against a putative role for DMHA in the genotoxicity and carcinogenicity 
of 2,6-xylidine in rats. 
5.5. Relevance to humans 
The maximum potential human 2,6-xylidine exposure deriving from 
approved use of lidocaine is 3.5 mg/kg/day. This is 35 × lower than the 
dose (>125 mg/kg/day) that induced metabolic overload and acute 
systemic toxicity in rats in this study, and which is identified as a no- 
effect level for potential genotoxic effects. 
Studies of lidocaine metabolism in humans (Keenaghan and Boyes, 
1972; Nelson et al., 1977; Tam et al., 1990), identify that a large part of 
the dose (63.5–80%) undergoes intrahepatic amide hydrolysis (a 
rate-limited process confined to the liver, catalysed by hepatic carbox-
ylesterase1A (Higuchi et al., 2013)) and is ultimately eliminated in the 
urine as conjugated DMAP. 2,6-xylidine itself, however, is generally 
undetectable or present at very low levels only in plasma, and consti-
tutes < 1–2% of the dose eliminated in the urine, despite high dose 
lidocaine infusions, such as for cardiac arrhythmia prevention or 
epidural infusion (Tam et al., 1987; Blankenbaker et al., 1975). Other 
potential metabolites of 2,6-xylidine (such as DMHA) have only been 
detected in trace amounts in urine (<1% of the dose) (Nelson et al., 
1974, 1978). These findings indicate that 2,6-xylidine, (produced as an 
intrahepatic metabolite of lidocaine), is rapidly and extensively con-
verted to DMAP, conjugated, and eliminated in the urine via a process 
that does not saturate, (such as to result in significant systemic 
bioavailability of 2,6-xylidine), despite high dose lidocaine infusions. 
Low level met-Hb formation (statistically significant but not biologically 
relevant) (Filipiak-Strzecka et al., 2015; Weiss et al., 1987; Hjelm and 
Holmdahl, 1965), as well as 2,6-xylidine-Hb-adduct formation (Bryant 
et al., 1994), have been reported following therapeutic lidocaine 
administration. Together these data suggest that 2,6-xylidine exposure 
following therapeutic lidocaine in humans is sufficient to result in low 
level haem oxidation of DMAP, (forming Hb-adducts), however (other 
than extremely rare cases with predisposing factors, detailed below) it is 
insufficient to overwhelm phase 2 metabolism of DMAP, glutathione 
detoxification of DMQI and cellular anti-oxidant defences, such as to 
reach a threshold for redox cycling and significant met-Hb production 
(with associated DMQI and ROS formation and potential cytotoxic or 
genotoxic effects). This is consistent with lack of evident genotoxicity of 
lidocaine and lack of any evident causative association with carcino-
genicity over 8 decades of extensive human use. 
Clinically significant met-haemoglobinaemia, although a well- 
documented complication of amide local anaesthetics such as benzo-
caine and prilocaine, is only extremely rarely reported in association 
with lidocaine administration (Chowdary et al., 2013; Guay, 2009; 
Vallurupalli and Manchanda., 2011; Gutenberg et al., 2013). This dif-
ference is attributed to the relatively low in vivo capacity of DMAP (the 
primary met-Hb forming metabolite of lidocaine, Higuchi et al., 2013) to 
form met-Hb, which, in vivo, requires threshold-affected metabolic 
activation. The N-hydroxylamine metabolites of the other local anaes-
thestics may induce met-Hb formation more directly (Hartman et al., 
2014, 2017). Nevertheless, rare cases of significant 
met-haemoglobinaemia are reported in settings in which large doses of 
lidocaine have been administered in combination with other oxidising 
agents (Karim et al., 2001), and/or in the presence of other factors that 
reduce or deplete glutathione, intracellular anti-oxidant or met-Hb 
reduction capacity. Neuhaeuser et al. (2008) for example, reported 
met-haemoglobinaemia following administration of lidocaine (13 ± 3 
mg/kg) to infants undergoing cranio-facial surgery, during which they 
also required major blood transfusion. A number of factors may have 
predisposed the infants to met-haemoglobinaemia in this setting. In 
addition to the high dose, young infants may have immaturity of; phase 
2 metabolism (Lu and Rosenbaum, 2014); erythrocyte met-haemoglobin 
reductase activity (Nilsson et al., 1990), and cellular uptake of cysteine, 
(which affects glutathione levels) (Lavoie et al., 2002). Furthermore, 
stored blood may be depleted in glutathione and have reduced gluta-
thione synthetase activity (Whillier et al., 2011). This highlights the 
importance of considering risk factors for threshold-affected metabolic 
activation of DMAP in patients with such risk factors. 
6. Summary and conclusions 
In summary, 2,6-xylidine appears resistant to N-hydroxylation and/ 
or activation to nitrenium ions. Instead, it predominantly metabolises 
via 4-hydroxylation to DMAP which, at high doses that are sufficient to 
saturate phase 2 metabolism, may undergo a threshold affected meta-
bolic activation pathway forming DMQI, with potential to redox cycle 
producing ROS, met-Hb and inducing secondary cytotoxic and genotoxic 
effects. A review of the literature (above) identified evidence that 2,6- 
xylidine has weak genotoxic characteristics in vitro and is able to 
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induce DNA damage in vivo, however, there were no clear positive 
findings that 2,6-xylidine exposure results in lasting genotoxic effects 
due to stable genetic damage. The results would support a threshold- 
dependent metabolic activation pathway, with cytotoxic and geno-
toxic effects secondary to DMQI redox cycling and ROS production, only 
evident at doses or concentrations sufficient to overwhelm phase 2 
metabolism of DMAP, glutathione detoxification of DMQI and cellular 
anti-oxidant defences. 
A new combined comet and MN study identified lack of in vivo 
genotoxicity in rats at non-toxic doses. A weak dose-related response for 
comets in male rat livers was considered not biologically relevant since 
all % tail DNA values fell within the historical negative control range, 
(“background noise”) and the low magnitude dose response was asso-
ciated with significant weight loss and systemic toxicity. Systemic toxic 
effects were of a nature as may have induced low-grade oxidative stress 
and contributed to the marginal comet dose response. Metabolic ana-
lyses confirmed DMAP as the predominant metabolite of 2,6-xylidine. 
Saturation of conjugated-DMAP production, associated with signs of 
acute systemic toxicity (indicative of metabolic overload), occurred at 
doses >125 mg/kg/day. DMHA was identified as a minor in vivo 
metabolite in hepatic tissue of male rats administered doses of 125 mg/ 
kg/day or greater, however it was not associated with increased comets 
at the 125 mg/kg/day (non-toxic) dose. These analyses confirmed that 
rat tissues were exposed to high levels of 2,6-xylidine, and to the me-
tabolites DMAP and DMHA. A mechanistic assessment was not possible 
in the absence of clearly positive genotoxic effects at non-toxic doses. 
Benchmark dose analysis of these data confirmed a non-linear dose 
response and allowed a conservative estimate of the PoD to be deter-
mined (97 mg/kg/day). Since there was no induction either for MN in 
bone marrow, or comets in nasal tissue or liver, at acceptable levels of 
toxicity, the no-effect doses for in vivo genotoxicity are concluded to be 
125 mg/kg/day in males and 400 mg/kg/day in females. 
In conclusion, there is no clear evidence that 2,6-xylidine or its 
metabolites induce genotoxic damage in vivo at doses that do not cause 
metabolic overload and acute systemic toxicity. 2,6-Xylidine appears 
resistant to metabolic activation via N-hydroxylation, and instead me-
tabolizes predominantly to DMAP, which (at doses sufficient to over-
whelm phase 2 metabolism) may undergo threshold-affected metabolic 
activation to DMQI, with potential to redox cycle producing ROS. 
Cytotoxic and genotoxic effects due to DMQI redox cycling and ROS 
production may be evident in vitro or in vivo where phase 2 metabolism 
of DMAP and glutathione detoxification of DMQI and/or cellular anti- 
oxidant defence systems are overwhelmed. However, in the latest 
study in vivo, no clearly positive genotoxic effects were seen, including in 
nasal tissue, despite dosing to the MTD. In liver, glutathione levels were 
not depleted prior to a threshold for metabolic overload (saturation of 
conjugated DMAP production with acute systemic toxicity) being 
reached. The weight of evidence therefore indicates that 2,6-xylidine is 
not a direct acting genotoxin or mutagen. It exhibits a PoD based on 
threshold-dependent metabolic activation, such that it is not genotoxic 
in vivo in the absence of acute systemic toxic effects. Exposure levels that 
maximally occur through approved therapeutic use of lidocaine in 
humans are at least 35 × lower than those that induce metabolic over-
load and systemic toxic effects in rats, consistent with lack of evident 
association between lidocaine use and cancer despite 8 decades of 
human therapeutic use. 
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